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Multiple myeloma, which is the second most commonly diagnosed 
hematologic malignancy, remains a fatal disease. It is highly heterogenous as 
characterized by the presence of multiple cytogenetic, molecular, proliferative 
profiles, and clinical course. p53, one of the most commonly mutated tumor 
suppressor gene in human cancer and located on chromosome 17p13, is found to 
be wild type (WT) in almost 90% of MM. Nevertheless, the frequency of p53 
abnormalities is more prevalent in the advanced stage of MM, suggesting possibly 
a crucial role for disease progression. This study focuses on elucidating the 
genetic abnormality in one of the high-risk myeloma groups, i.e. the cases 
presenting with hemizygous deletion of 17p13. This cytogenetic abnormality has 
been identified in more than 20% of MM patients and is significantly associated 
with poor prognosis. Standard treatment regime is inadequate for this group of 
patients with a high incidence of drug resistance, underscoring the urgent need for 
new and improved treatments.  
To devise more effective treatments for these high-risk patients, we have 
to first demonstrate that the important gene on 17p13 is TP53 and then further 
dissect its functional role in myeloma. This is imperative because to date, there is 
no conclusive evidence that p53 is the critical gene in the 17p13 region. 




Herein, by utilizing human myeloma cell lines as study models 
representing the spectrum of different p53 abnormalities, we showed that TP53 
hemizygous loss was associated with decreased basal expression level of p53 with 
a partially or severely inactivated p53 response upon genotoxic and non-genotoxic 
stress. MDM2 over-expression, TP53 promoter hypermethylation and over-
expression of onconmiR- 25 and -30d appeared to be important in silencing the 
remaining p53 allele in some cases with p53 WT/-. We also developed a p53 
target gene signature to summarize the complexity of the p53 pathway 
abnormalities.  
Importantly, we showed that the novel p53-reactivating agents, nutlin-3 
and PRIMA-1, hold substantial promise as potential therapeutic avenues for high-
risk patients with p53 pathway abnormalities. Nutlin-3 could be potentially used 
to target the 17p13(del) cases with p53 expression. Whereas, for those who have 
an absence of p53, PRIMA-1 could be very useful because we identified that this 
drug was conferring a higher cytotoxicity in a p53-deficient background. When 
probed further, an important involvement of ER stress pathway was unveiled.  
In conclusion, this study has comprehensively dissected the importance of 
TP53 being a driver gene in myeloma with 17p13 deletion, and revealed that p53 
is a haploinsufficient tumour suppressor in MM. Therefore, the data generated 
contains important translational value that serves as a stepping stone for future 
development of clinical biomarkers and novel therapeutics which manipulate the 
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CHAPTER 1: INTRODUCTION 
 
1.1 Cancer and Multiple Myeloma (MM) 
Cancer is a pathological condition which involves the transformation of 
normal cells to malignant state. In cancer, cells lose the integrity of cell cycle 
regulation resulting in uncontrolled growth and proliferation. The tumor mass 
formed, if uncontrolled, would invade nearby parts of the body. As the disease 
progresses, the cancer may spread to more distant parts of the body through the 
lymphatic system or bloodstream, a condition known as metastasis. Cancer 
research in the past has unveiled the complexity of the disease whereby tumor 
pathogenesis has been shown to stem from multistep processes, where sequential 
mutations of critical genes leads to acquisition of different cancer properties, the 
so-called hallmarks of cancer [1]. Acquisition of several of these traits would 
allow the cells to override normal cellular proliferation and to escape homeostasis 
regulation, and transform them into malignant cells. The six biological 
capabilities that are important for tumor formation and progression have been 
classified as persistent proliferative signaling, resistance to cell death or apoptosis, 
immortality in replication, insensitivity to signals from growth suppressors, 
sustained induction of angiogenesis and activation of invasion and metastasis 
factors [1].  
Hematologic malignancies are cancers deriving from blood, lymph and 
bone marrow.  Multiple myeloma (MM) is a type of hematologic malignancy of 
lymphoid origin involving dysregulation of plasma cell growth [2]. MM is the 
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second most commonly diagnosed hematologic malignancy, accounting for 
almost 15% of blood cancer and 1% of all types of human cancer [3-5].  In 
normal condition, mature B cells undergo somatic hypermutation, antigen 
selection and immunoglobulin H (IgH) switching in the germinal center, which 
upon antigenic stimulation; they migrate to the bone marrow and differentiate into 
antibody-producing plasma cells. MM is characterized by an excessive expansion 
of monoclonal plasma cells in the bone marrow. In line with the antibody-
producing role of plasma cells, proliferation of these cells leads to the 
overproduction and spillage of monoclonal immunoglobulin into the serum and/ 
or urine [2, 6].  These proteins are labelled as M protein or Bence-Jones protein 
and its presence in the serum or urine is one of the diagnostic criteria. On top of 
that, patients usually present with clinical symptoms such as hypercalcemia, renal 
failure, anemia and lytic bone lesion and these manifestations are abbreviated as 
CRAB.  
MM is a slow growing tumor due to its low proliferative capacity [6, 7]. 
This disease can arise sporadically or follow a series of stages before the full 
blown disease is manifested. Of importance, MM is commonly preceded by a pre-
malignant condition called Monoclonal Gammopathy Of Undetermined 
Significance (MGUS), which is the most common lymphoid neoplasia in humans, 
with increasing incidence rate in patients over the age of 50 [2, 8]. This stable pre-
malignant stage can progress to symptomatic MM at a rate of between 0.5–3.0%, 
depending on the initial level of monoclonal immunoglobulin [6, 9]. Smoldering 
myeloma (SMM) is an intermediary stage between MGUS and symptomatic MM 
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[6, 10]. It is a stable disease which requires no treatment but close monitoring for 
hints of progression. When composition of malignant plasma cells in the bone 
marrow exceeds 30% alongside the presence of monoclonal protein (Bence-Jones 
protein) in serum and/ or urine as well as in the existence of CRAB syndrome, the 
patient will be diagnosed with MM. The diagnostic criteria for these three stages 
of plasma cell disease are depicted in Table 1.1 [8]. Plasma cell leukemia (PCL) is 
the most aggressive plasma cell neoplasm where there is a spillover of the cells 
into the peripheral blood causing the deposition of MM cells in extramedullary 
regions [6, 11]. Even though not all cases follow this course of progression 
(MGUS, SMM, MM, PCL), the sequential process has been generally accepted 
and has been optimally used as a study model to gain in-depth understanding of 
its pathogenesis. In order to cater to the needs of scientific research of this disease, 
human myeloma cell lines (HMCL) have been established and they are mostly 
generated from tumors obtained from the extramedullary sites [2], rendering these 
cell lines to harbor various chromosomal and genetic abnormalities. 
Disease heterogeneity is a characteristic of MM with a multitude of 
genetic and epigenetic alterations. Majority of MM harbours chromosomal 
translocation, resulting in the juxtaposition of oncogenes to the active promoter 
driven by IgH. For instance, t(4;14) which carries adverse prognostic values is 
associated with over-expression of oncogenes FGFR3 and MMSET  [7, 12, 13]. 
Other common abnormalities that have been reported in MM are loss of 
chromosome 13, p16 hypermethylation, miRNA deregulation, RAS mutations and 
17p13 deletion [2, 14-17]. The list of the abnormalities is non-exhaustive owing 
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to the availability of high throughput technology such as microarray profiling and 
next generation sequencing which allow for cutting-edge research in the 
identification for new and relevant genetic and epigenetic aberrancies.  
Despite an increase of understanding of the disease, MM remains 
incurable. The prognosis in the patients is generally severe, with only 
approximately 3 years of median survival from diagnosis [18]. Chemotherapy 
coupled with bone marrow stem cell transplantation remains the gold standard 
treatment for the patients. The emergence of promising drugs such as bortezomib, 
thalidomide and lenalidomide have improved the patients’ outcome [5, 19, 20]. 
Nevertheless, drug resistance remains a ubiquitous event in MM. Even in cases 
where the response rate to initial treatments is high, many of these patients 






Table 1.1 Diagnostic criteria for plasma cell disorder from asymptomatic 






















1.2 p53 tumor suppressor 
 
 1.2.1 Structure of p53 protein 
 Located at the chromosome 17p13.1 locus, TP53 encodes the p53 tumor 
suppressor protein. This 393 amino acids long protein consists of five functional 
domain, namely, the amino-terminal transactivation domain (aa 1-50), the proline-
rich domain (aa 63–97), the central DNA-binding domain (DBD: aa 102–300), 
the tetramerization domain (aa 326–358) and carboxy terminal domain (basic 
domain) (aa 363–393) (Fig. 1.1) [21]. Each domain has distinct functions in 
modulating the tumor suppressive properties of p53.  
The transactivation domains are responsible for the activation of specific 
downstream target genes. This region is also subjected to various post-
translational modifications leading to the activation of p53 protein.  The proline 
rich domain has been reported to be mediating the p53 functions in DNA damage-
induced apoptosis [22]. DNA binding domain or the core domain of the protein is 
important in binding to the p53 responsive elements on the promoter region of 
target genes via sequence specific recognition. Through its binding, p53 can then 
transactivate or transrepress a series of downstream targets [23, 24]. Finally, the 
tetramerization domain plays a role in the formation of dimers and tetramers of 
the protein. This step is essential as p53 by itself as a monomer is biologically 
inert and only in the tetrameric form can it bind to the consensus responsive 
elements on the target genes. The carboxy terminal region of the protein functions 
as a non-specific DNA binding domain that is essential for the transactivation of 
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certain subset of genes, and has been implicated to serve as a positive regulator of 




Figure 1.1. Schematic representation of p53 protein structure consisting of 
distinct functional domains. [Adapted from: http://p53.bii.a-star.edu.sg/aboutp53/]  
 
 
1.2.2 The p53 network 
 p53 was the first tumor suppressor gene that has been identified and is 
probably the most frequently studied tumor suppressor in cancer history [24, 26]. 
Deemed the guardian of the genome, p53 safeguards the integrity of the genome 
and ensures that the tissue homeostasis is kept in check. Under normal 
physiological conditions, cellular p53 is expressed at low levels, thereby, turning 
off the activity of p53 network. It is a labile protein with a very short half life 
ranging only from 5 to 30 minutes, owing to the rapid degradation by its main 
negative regulator Mouse Double Minute 2 Homolog (MDM2) [27]. Importantly, 
MDM2 itself is a p53-inducible gene. Thus, the two molecules interact with each 
other through an auto-regulatory negative feedback loop aimed at maintaining low 
cellular p53 levels in the absence of stress. MDM2, is an E3 ubiquitin ligase 
which binds to and inhibits the transactivation domain of p53, and concurrently 
promotes mono- and poly-ubiquitination of p53, subsequently subjecting the 
tumor suppressor protein to rapid proteosomal degradation. It has been reported 
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that mono-ubiquitination of carboxy terminal domain activates the nuclear export 
signal in the adjacent tetramerization domain of p53 and allow the protein to be 
exported into cytoplasm, thus, inhibiting its functional transcriptional activity [27].    
 The induction of the p53 activity is governed by various post-translational 
modifications, including phosphorylation, acetylation, neddylation, sumoylation 
and ubiquitylation when the cells are subjected to various stress stimuli such as 
DNA damage, hypoxia, oncogene activation, viral infection and telomere erosion 
[24, 28]. Most of these modifications occur in the amino- and carboxy-terminal 
regions of p53. Phosphorylation, being the main modification mode in response to 
DNA damaging agents, for instance, ionizing radiation and chemotherapeutic 
drugs, is mediated by a series of kinases, namely, ATM, ATR and DNA-PK, 
which are facilitated by their downstream checkpoint kinases Chk1 and Chk2. 
This mode of post-translational modification releases p53 from MDM2 control, 
rendering the stabilization and accumulation of p53 which ultimately results in the 
massive activation of the downstream signaling, after which a range of diverse 
anti-growth and proliferation as well as pro-apoptotic genes are actively 
transcribed [24, 28].   
A classic tumor suppressive function of p53 in response to DNA damage 
is by firstly inducing growth arrest to permit cells to undergo DNA repair before 
allowing the cells to regain entry into the cell cycle phases [23]. This step is 
important in ensuring that the DNA damage or any possible genetic mutation is 
not passed on to the progeny cells. However, when the damage becomes too 
extensive and is beyond repair, p53 would switch its functional role to inducing 
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apoptosis, thereby eliminating the damaged cells altogether [26, 28]. These 
physiological responses serve as a protection from genomic instability and 
tumorigenesis.    
In order to execute its anti-proliferative and pro-apoptotic mechanisms, 
p53, acts as a transcription factor to transactivate a broad spectrum of targeted 
genes in a sequence specific manner. The consensus DNA sequence for p53 
binding is RRRCWWGYYY, where R is a purine, W is A or T and Y is a 
pyrimidine. With the advent of nouveau scientific technologies including the likes 
of SAGE, microarray and CHIP-Seq, the list of p53 direct targets is lengthy [29]. 
Nevertheless, many p53 direct targets have been experimentally validated and 
they are pivotal in the orchestration of anti-tumorigenic programmes by mediating 
processes such as cell cycle arrest (p21 and 14-3-3σ), DNA repair (GADD45 and 
p53R2), apoptosis (BAX, PUMA and NOXA) and senescense (p21) [23, 30]. 
Simultaneously, p53 also transcriptionally repress several pro-survival genes such 






Figure 1.2. The p53 network in response to cellular stresses [23]. When activated, 
p53 transcribes various downstream target genes mediating tumor suppressor 




In addition to that, p53 also has a transcription independent role (Fig. 1.3). 
In this instance, p53 is localized in the cytosol or mitochondria. Upon stress 
induction, cytosolic p53 acts by binding to the anti-apoptotic BCL-2 family 
protein, namely BCL-2, BCL-xL and MCL-1, on the mitochondrial membrane 
thereby releasing pro-apoptotic BAX and BAK from these negative regulators. 
Additionally, p53 can also bind directly to BAX and BAK, after which they 
would then homo-oligomerize within the outer mitochondrial membrane to induce 
mitochondria outer membrane permeability (MOMP). On top of that, BH3-only 
protein such PUMA, NOXA and BAD also aid in the sequesteration of p53 from 
BCL-XL and MCL1. This will then allow the freed p53 to bind directly to BAX 
[31]. MOMP is accompanied by the release of pro-apoptotic factor cytochrome C, 
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which in combination with APAF1 (also another p53 direct target) and caspase-9, 
forms apoptosome complexes and executes apoptosis [30, 31]. This mechanism is 




Figure 1.3. Transcription-independent function of p53 [31]. This mechanism 
takes place in the cytoplasm, mediated by a series of BCL-2 family members to 




The role of p53 has also been implicated in extrinsic apoptotic pathway. 
The tumor necrosis factor (TNF) family of death receptors or transmembrane 
proteins CD95/Fas/APO-1, DR5/KILLER/TRAIL and PERP are direct 
transcriptional targets of p53 [32]. Thus, increased transcription of these proteins 
by p53 in response to stress enhances the sensitivity of cells towards apoptosis. 
The extrinsic apoptosis is often considered as an augmenter to cell death 
responses induced by the transcription-dependent mechanism. This is because the 
intrinsic response has been described as the necessary and sufficient executioner 
in the process [33] . The activation of the extrinsic pathway is initiated by the 
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binding of ligands to the transmembrane receptors which leads to the formation of 
Fas-Associated protein with Death Domain (FADD) and TNF receptor-associated 
death domain (TRADD). These death domains are adaptor molecules which 
bridge the ligand-receptor complexes to caspase-8, to form death induced 
silencing complex (DISC) that will then execute the apoptotic responses [32, 33].  
Another main phenotypic response of p53 under stress is cell cycle arrest. 
In this instance, CDKN1A is one of the most important genes in mediating the 
p53-dependent cell cycle arrest by encoding for a Cylin-Dependent Kinase 1 
(CDK1) inhibitor, p21/WAF1. By binding to the kinases, p21 inhibits the 
progression of the cells from G1 to S-phase by activating downstream Rb tumor 
suppressor protein which would suppress the actions of E2F transcription factor 
from transactivating the genes involved in cell cycle progression [34, 35]. p21’s 
role has also been indicated in p53-dependent- cell senescense, which is a process 
of permanent growth arrest in response to extreme stress induction [35]. On the 
other hand, the p53-dependent-halting of G2 phase in the cell cycle is modulated 
by GADD45 and 14-3-3σ [36-38]. 
Since p53 executes its tumor suppressive properties via two main 
mechanisms, namely cell cycle arrest and apoptosis, it has not been fully 
elucidated as to what type of response the cells would choose to undergo when 
subjected to DNA damage. The exact criteria that influence p53 to stimulate cell 
cycle arrest or apoptosis are only partially understood and are the subject of 
intense study.  
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The main contributing factor for the choice of p53 responses would be the 
intensity of DNA damage [28]. Mild DNA damage has been said to induce 
growth arrest to allow for recuperation time for the DNA while severe damage 
that is beyond repair capacity almost always leads to apoptosis. Besides, level of 
p53 expression has also been described as one of the main factors contributing to 
the choice of mechanism [39]. It has been shown that low p53 expression usually 
confers cell cycle arrest while high p53 expression managed to trigger full blown 
p53 responses with efficient transactivation of pro-apoptotic genes, leading to 
apoptosis [39]. Previous studies have also reported the anti-apoptotic effects of 
p21 whereby its over-expression tilts the cells choice to cell cycle arrest rather 
than apoptosis [34, 40]. This concept comes from an initial study whereby two 
point mutations of p53 at Pro175 and Leu18 retained the ability to cause p21-
mediated-G1 arrest but failed to suppress the transformation of cells by oncogene 
such as HPV E7 [41]. These mutants showed loss of p53 apoptotic activity and 
absence of pro-apoptotic gene expressions. The findings suggest that the slight 
conformational change caused by the mutations alters the p53 affinity binding 
whereby promoters of the cell cycle genes have higher affinity for binding p53 
than the pro-apoptotic genes. The differential binding affinity may also explain 
the choice that the cells undertake under high and low p53 expression [28]. 
Several other factors that have also been reported to influence the cells decision 
include the types of stress signals and the mode of post translational modifications 




1.3 Abnormalities of p53 in Cancer 
The integrity of the p53 pathway imparts an important role in maintaining 
the integrity of the genome which explains why the inactivation of p53 is a 
common event in human cancer. The increased susceptibility of patients with p53 
germline mutations succumbing to a wide range of cancer in Li-Fraumeni 
syndrome [42] is a testament of p53 being an important tumor suppressor gene.  
The first p53 mutation associated with human cancer was identified in 1989 in 
colon cancer [43]. Till date, 50% of all types of human malignancies have been 
detected with p53 mutations in the somatic cells, resulting in the loss of its tumor 
suppressive functions (Fig.1.4) [28, 44, 45]. In contrast to other tumor suppressor 
genes which are often inactivated through the complete loss of its protein 
expression attributed to large deletions and frameshift mutations, p53 is almost 
exclusively (95.6%) inactivated by missense point mutation at the DNA binding 
domain [24, 28] (Fig. 1.5). p53 residues 175, 245, 248, 249, 273 and 282 (Fig. 1.5) 
are considered the hotspots as they have been found to be the most commonly 
mutated locations (28%) in human cancer[28] . Mutation at the DNA binding 
domain yields a transcriptional defective p53, thus, decreasing or abolishing 
altogether the ability of p53 to transactivate the downstream genes. Due to the fact 
that various important pro-apoptotic genes are direct targets of p53, the inability 
of mutant p53 in transcribing these genes gives rise to a condition that is resistant 
to apoptosis in these cells. This ultimately explains the reason why tumors with 
p53 mutations are often non-responsive to standard chemotherapeutic treatment as 






Figure 1.4. Frequency of p53 mutations in different types of human cancer. 




Figure 1.5. Common hotspot mutations at the core domain of p53 [186].  
 
Mutated p53 protein has also been reported to have dominant negative 
roles whereby incorporation of mutant p53 into the p53 tetramer caused a severely 
compromised tumor suppressive function function of wild type p53 in the 
oligomer [46, 47]. Besides, mutant p53 was shown to harbor pro-oncogenic 
properties that are known as ‘gain-of-function (GOF)’. Over-expression of these 
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p53 mutants in p53-null cells resulted in transformation whereas the converse 
experiment, in which mutant p53 protein levels were knocked down in cancer cell 
lines, rescued the cells from oncogenesis [44]. The notoriety of GOF is 
manifested by a multitude of mechanisms. For instance, GOF was found to 
inactivate Mre11/ATM-dependent DNA damage responses, leading to 
chromosomal translocation and defective G2/M checkpoint [48]. Considering that 
ATM is the classical initiating point to the response for chemotherapy-induced 
genotoxic stress, abolishment of the ATM mediated pathway conferred resistance 
towards the chemotherapeutic treatments. Furthermore, Cooks et al. has 
demonstrated that mice with endogenous mutant p53 had prolonged activation of 
NFKB pro-survival signaling pathway, which rapidly succumbed to chronic 
inflammation-associated colon cancer [49]. Mutant p53 has also been shown to 
transcriptionally repressed tumor suppressor miRNAs leading to the over-
expression of their target oncogenes [50, 51]. In addition, it was also proposed 
that the mutant protein interacts with p63/p73, both of which are p53 sub-family 
members with 95% homology to the DNA binding domain of p53. The p63/p73 
interaction with mutant p53 inhibits the tumor suppressive functions of the former 
[52].  
 Besides mutation, the remaining 50% tumors containing wild type p53 is 
inactivated via various other mechanisms. Of importance, MDM2, the main 
negative regulator of p53, is deregulated in various cancers, including melanoma, 
breast cancer and colorectal cancer [53, 54]. Deregulation of MDM2, such as 
amplification of its gene gives rise to the over-expression of its protein, thereby 
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increasing the turnover rate of p53, keeping p53 level low at all times, and 
ultimately suppressing its tumor suppressive actions.  
MDMX is a homolog of MDM2. It does not have E3 ubiquitin ligase 
activity but it inactivates p53 by binding to and inhibiting the transactivation 
domain of p53. Due to its essential role in inactivating p53, MDMX dysregulation 
in cancer has also been receiving important attention [53, 54]. In fact, MDMX 
was said to enhance the E3 ligase activity of MDM2, thus, increasing the p53 
proteosomal degradation rate [53, 55].  
Furthermore, epigenetic regulation of TP53 is also a subject of intense 
research lately. MiRNAs are a set of non-coding RNA of 19 to 25 nucleotides 
long that plays a major role in regulating gene expression by degrading its target 
coding mRNA and by repressing protein translation through base pairing to 
partially or fully complimentary sites on target mRNA [56]. Studies on the 
miRNA regulation on p53 expression have identified few important miRNAs 
(miR-25, miR-30d, miR-504 and miR-125b) directly targeting the 3’-UTR of p53 
which subsequently resulted in the suppression of p53 protein expression and 
increased proliferative capacity of the cancer cells [57-59]. Moreover, it has also 
been previously reported, though not common, that the expression of TP53 is 
suppressed by promoter methylation in cancer [60-62]. Additionally, in response 
to stress, p14ARF is a protein that binds to and inhibits the activities of MDM2 by 
sequestration in the nucleolus. The absence of ARF expression through aberrant 
promoter hypermethylation has been regarded as an important mechanism of 
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suppressing p53 functions, as its absence renders MDM2 to be freely available to 
bind to and suppress p53 functions [24].  
It has been established that the main tumor suppressive function of p53 is 
executed via its transcriptional role in the nucleus. Therefore, the shunting of p53 
into the cytoplasm is said to be another means of inactivating the protein, though 
recent evidences have established non-transcriptional function of p53 in the 
cytoplasms [24]. Mono-ubiquitination of p53 by MDM2 has been described to be 
one of the sources of p53 cytoplasmic translocation [27]. 
For blood cancer, it is a common scenario that the cells acquire TP53 
genetic abnormality by undergoing monoallelic deletion [19, 63-65]. In these 
cases, the remaining allele was always inactivated by either somatic mutations or 
other alternative mechanisms described above, to drive p53 loss of heterozygosity 
(LOH). 
In summary, on top of the commonly reported missense mutations, the 
wild type p53 in cancer cells is subjected to various possible mechanisms of 










1.4 p53 abnormalities in multiple myeloma 
 
1.4.1 p53 mutation 
In contrast to all other types of human cancer, p53 abnormalities in 
hematological malignancies are uncommon events. In MM, mutation of p53 gene 
is a rare occurrence at diagnosis; however, the incidence increases in the 
advanced stage of the disease, suggesting its essential role in disease progression 
[65-67]. Overall, p53 mutations were found to occur in about 3% of newly 
diagnosed patients [19, 65-67]. The next generation sequencing methods that were 
recently employed into p53 mutational studies have also recapitulated the 
previous findings of low incidence rate of p53 mutations in MM [65, 66]. In view 
of the rare occurrence of p53 mutations in MM, it has been regarded as a non-
significant prognostic factor [66, 68]. Nonetheless, it is often associated with poor 
prognosis and account for significantly low survival rate [66, 67].  
 
1.4.2 p53 monoallelic deletion 
Deletion of chromosome 17p13 region, which bears p53 gene locus, is a 
recurrent cytogenetic abnormality in MM.  As p53 gene is housed at 17p13 region, 
much attention has been channeled to the studies involving incidence and 
prognostic impact of TP53 deletion in MM, thereby establishing its correlation 
with 17p13 deletion. Essentially, in clinical cases with 17p13 deletion, they were 
found to be predominantly mono-allelic and the remaining allele of p53 is rarely 
mutated [19, 65]. It has been demonstrated that hemizygous deletions of TP53 
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was found in approximately 10% to 34% of clinical cases [66, 67, 69, 70]. 17p13 
deletion is associated with poor outcome [19, 20, 65, 67, 71], and used to define 
high-risk myeloma [72, 73].  
In particular, Chang et al. reported that hemizygous 17p13 deletions were 
prevalent in cases with central nervous system involvement in MM and this marks 
the association of this genetic abnormality with the metastatic properties of 
myeloma cells [74]. This report is in line with Elnenaei and colleagues’ finding of 
the higher percentage of patients with p53 deletions having stage IIIb disease or 
plasma cell leukemia, with advanced stage of organ infiltrations [73, 75]. This 
study has also shown that monoallelic deletion of p53 was the only variable 
associated with resistance to chemotherapy. Moreover, another recent study has 
reported a more rapid progression of MM to plasma cell leukemia in 17p13(del) 
cases as compared to patients without this abnormality [76]. Loss of p53 function 
has also been associated with upregulation of IL-6 production, which MM cells 
depend on for its growth and proliferation [61]. Essentially, loss of p53 has also 
been reported to be important in the progression of MM which involved 
reprogramming of the hematopoietic progenitor cells to malignant plasma cells 
[77]. Additionally, thalidomide, a promising new anti-myeloma agent did not 
bring about an improved overall survival in these high risk patients [19]. These 
findings collectively testified the important role of p53 deletions in the disease 
process. p53 deletion has also been closely linked to low expression of the gene 
(indicating haploinsufficiency) which was seen in 10% of newly diagnosed 
patients, with inferior clinical outcome [19, 70, 78].  
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1.4.3 Other mechanisms of p53 inactivation in multiple myeloma 
50% of human cancers harbours p53 mutations, while in the remaining 
50%, the wild type p53 is deemed to lose its function via various mechanisms that 
affect the expression and activity of p53.  As described in the earlier section, the 
main inhibition of wild type p53 is the amplification or over-expression of its 
negative regulator MDM2. Of importance, MDM2 has also been found to be 
deregulated in MM [73, 79, 80]. Over-expression of MDM2 was shown to be 
essential in promoting both the entry into cell cycle and tumor cell survival in 
myeloma cells [79]. Essentially, even though the incidence of MDM2 over-
expression is infrequent, these patients were presented with poor prognostic 
features [80], indicating its pivotal role in the disease process.  
Furthermore, the dysregulation of MDM4 is also relevant in the 
perspective of MM because amplification of chromosome 1q, a region at which 
MDM4 gene resides in, has been established as an independent and significant 
prognostic factor [2, 81]. Indeed, patients harbouring this abnormality are 
categorized in the subgroup of high risk-MM [81].  
On top of that, rigorous research on aberrant expression of miRNAs in 
cancer has led to the hypothesis of the role of this group of non-coding genes in 
the pathogenesis of MM [56, 82]. Importantly in MM, studies on the miRNA 
regulation on p53 expression have identified that both miR-25 and miR-30d can 
directly target the 3’-UTR of p53 mRNA and subsequently resulted in the 
decrease of p53 protein expression, depletion of the apoptosis response rate and 
diminishment of cellular senescence [57]. Introduction of the specific inhibitors of 
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miR-25 and miR-30d in a HMCL, NCI-H929, in turn increased the endogenous 
level of p53 protein, which is accompanied by the upregulation of pro-apoptotic 
gene PUMA and ultimately the increase of apoptosis [57].  Pichiorri et al. has also 
demonstrated that the tumor suppressor miRNAs, namely, miR-192, 194 and 215 
were downregulated in myeloma samples. Mechanistically, these miRNAs exert 
its anti-myeloma effects by suppressing the p53-negative regulator, MDM2 [83]. 
In line with this, over-expression of miR-214 was shown to induce the increase 
p53 transcripts, with a concurrent reduction in myeloma cellular growth [84]. 
These findings indicate the vital role of miRNA deregulation in myelomagenesis.  
In addition, epigenetic factors could also be regulating the expression and 
the activity of p53. For instance, the deregulation of p14ARF has been reported to 
be responsible in abolishing the integrity of the p53 pathway [85]. ARF has an 
essential role in sequestering MDM2 in the nucleolus and downregulating its 
expression level, thereby, reinstating the stability of p53 which then leads to the 
activation of its downstream pathway [24]. Hypermethylation of p14ARF has 
been described in various tumors [24, 86, 87] and more importantly, this 
epigenetic abnormality has also been reported in MGUS and MM samples [88]. 
This finding reflects a situation whereby p14ARF hypermethylation acts as an 
early event in the pathogenesis and development of MM. 
Hypermethylation of the promoter region of TP53 gene itself has also 
been demonstrated in HMCLs [61, 89]. Reversal of this epigenetic alteration by 
zebularine (DNA methyltransferase inhibitor) restored the expression of p53 in 
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the cells followed by decreased in cell viability and increased in apoptosis [61, 
89]. 
Collectively, these findings indicate that p53 can be inactivated through a 
diverse range of mechanisms in promoting myelomagenesis. 
 
1.5 p53 reactivating agents in cancer and myeloma 
Due to the fact that p53 is the nexus of various tumor suppressive 
pathways, it is pivotal to study the means of reactivating or restoring p53 
functions in human cancer in order to rescue the resistance of the cells towards 
standard chemotherapeutic treatments. In fact, many anti-cancer drugs induce 
apoptosis through multiple pathways that are at least in part dependent upon 
functional p53 activation. Introduction of wild-type p53 gene into a variety of 
human tumor cells was shown in the late 1980s and early 1990s to induce 
efficient growth inhibition and apoptosis [90]. In line with this, multiple efforts 
have been channeled into researching for effective p53-based therapy. In fact, p53 
gene therapy (Gendicine) has been approved as the standard treatment for various 
cancers in China [90]. Its US counterpart, Advexin has also shown some efficacy 
in a number of clinical trials. 
In myeloma, pre-clinical study demonstrated that adenovirus-mediated 
delivery of wild type p53 could potently induce apoptosis in myeloma cells with 
low expression of BCL-2, while sparing the normal hematopoietic cells and 
normal lymphocytes [91]. Furthermore, in an attempt to elucidate the p53 network 
in MM, a group of scientists triggered an over-expression of p53 protein in a set 
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of human MM cell lines, and they found a reduction in cell viability, together with 
an increased rate of apoptosis and cell cycle arrest. This indicates the importance 
of functional p53 in arresting the development of myeloma as well as the 
progression of the disease. With the objective of reactivating the p53 pathway, 




 Due to the fact that newly diagnosed cases of MM are often presented 
with wild type p53, therapeutic induction of p53 is an attractive treatment strategy 
for this disease. The most conventional way of inactivating wild type p53 has 
been reported to be the deregulation/ over-expression of MDM2. In view of this, 
the development of drugs to reactivate wild type p53 has focused on developing 
small molecule inhibitors to the MDM2-p53 complex. In this context, the first 
reported and the most well studied drug is the nutlins [90]. Nutlins are a group of 
cis-imidazole analogs (Fig. 1.6A), with high affinity towards the p53-binding 
pocket on the amino terminal of MDM2 [92, 93]. Nutlin was shown to resemble 
three important residues (Phe19, Trp23 and Leu26) on the transactivation domain 
of p53 that are critical for MDM2 binding (Fig. 1.6B) [93] . In other words, nutlin 
competitively displaces p53 from the binding on MDM2 and effectively causing 
the stabilization of p53. Accumulation of p53 protein subsequently leads to its 
downstream pathway activation in cancer cells with wild type p53. Figure 1.6C 
depicts the mechanism of action of nutlin.  
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 Nutlin-3 has been shown to be a potent inducer of apoptosis in cell lines 
derived from hematological malignancies, including MM, ALL, AML, CLL and 
Hodgkin’s lymphoma [4, 94]. In MM, nutlin-3 demonstrated a potent anti-
myeloma activity in MM cell lines, primary MM patient samples and MM cells 
grown in the bone marrow microenvironment [4, 95]. It was shown to reactivate 
the p53 pathway of the cells with wild type p53 by inducing the transcription of 
its downstream targets, p21 and MDM2 alongside the pro-apoptotic genes, 
PUMA, BAX and BAK, which subsequently triggered cell death [4, 95]. This 
effect was observed specifically only in wild type but not mutant p53 cells [4, 95]. 
The molecular mechanisms behind nutlin-induced apoptosis in MM were 
associated with both p53-transcription dependent and independent pathways [95]. 
Imperatively, nutlin-3 was found to be lacking toxicity towards normal bone 
marrow hematopoietic cells. In fact, it was demonstrated to have an anti-growth 
instead of apoptosis-inducing effects on the normal hematopoetic stem cells [4]. 
This finding indicates the promise that nutlin-3 holds as a non-genotoxic drug for 
killing myeloma cells with minimal side effects. Furthermore, nutlin-3 displayed 
wide synergy with various conventional chemotherapeutic drugs, namely 
melphalan, etoposide and velcade [4, 96, 97]. Taken together, these studies 
demonstrated the potential of nutlin-3 being used as a novel treatment for MM 













Figure 1.6. Nutlin-3 and its mechanism of action [93]. (A) Chemical structure of 
Nutlin-3. (B) Crystal structure of nutlin-3 (shown as sticks) and MDM2. Nutlin 
competitively binds to the p53 binding sites on surface of MDM2 (Phe19, Trp23 
and Leu26). (C) Occupancy of small molecule nutlin-3 on the surface of MDM2 
protein, displacing p53 from its negative regulator, thus stabilizing the tumor 









1.5.2 p53 reactivation and induction of massive apoptosis (PRIMA-1) 
p53 mutations are often associated with resistance to chemotherapy 
treatment in cancer [49-51, 59]. These findings, together with the fact that mutant 
p53 are often expressed at high levels, render mutant p53 to be an important target 
for cancer therapy. In view of this, p53-mutant-reactivating agents have been 
developed. One such agent is the p53 reactivation and induction of massive 
apoptosis (PRIMA-1). PRIMA-1 (Fig. 1.7) is a small molecule drug that 
reactivates mutant p53 by restoring its wild type conformation, and hence, its 
transcriptional activity and its tumor suppressive functions. At the molecular level, 
PRIMA-1 is converted into its active by-product, methylene quinuclidinone (MQ) 
from its parental substance at 37oC [98]. MQ then binds to and forms adduct with 
the thiol group- containing cysteine (Cys) residues on the core domain of the 
mutant p53, thus, modifying and restoring its wild type protein conformation. 
This covalent modification of the mutant protein is sufficient to restore its binding 
ability to its transcriptional targets [98]. Since mutant p53 are often overexpressed 
in cancer cells, the restoration of wild type function in these high number of 
mutants ultimately trigger massive apoptosis. 
The classical function of PRIMA-1 in reactivating mutant p53 has been 
well established in the human cancers, namely, breast cancer [99], small cell lung 
carcinoma  [100] and thyroid cancer [101]. This drug was able to restore the 
functional p53 pathway by inducing the transcription of various downstream 
targets (p21, MDM2 and BAX) and a consequent mutant-p53-dependent 
apoptosis [99, 100, 102]. It has also been shown that this drug has good anti-
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tumor effects in vivo, whereby it potently inhibits the growth of tumor in human 
tumor xenograft models [102]. Interestingly, despite its well-established 
mechanism of action, mutant-p53-independent effects of PRIMA-1 have also 
been documented. However, it has only been implicated in a handful types of 
tumors, namely the small cell lung cancer [100], prostate cancer [103] , breast 
cancer [104] and hepatocellular carcinoma [105], indicating a rarely explored area 
of research for a drug that has been found more than 10 years ago [106].  
PRIMA-1 was also shown to synergize with various chemotherapeutic 
agents to induce cancer cell death [107, 108]. Due to its promising anti-cancer 
properties, PRIMA-1Met/APR246 (Fig. 1.7), a more potent derivative of the first 
generation drug was developed and is now in Phase I/II clinical trials [109]. 
Experimental testing on Saos-2-His 273 mutant p53 cells revealed a higher IC50 
of PRIMA-1 (14uM) as compared to its methylated derivative (9uM) [98]. 
The potency of PRIMA-1 in hematological malignancies came to light 
when it was found to have an anti-leukemic effect in CLL and AML cells [108, 
110]. Interestingly, it was found to be more cytotoxic to AML cell with 
hemizygous p53 deletion [108], giving rise to the possible clinical applicability of 
this drug in MM since patients with p53 deletion often have very poor outcome. 
Indeed, a recent report from Saha et al showed that PRIMA-1 can induce 
apoptosis in several HMCLs irrespective of p53 status [111]. The authors further 
demonstrated that PRIMA-1 toxicity was mediated by p73 (the p53 subfamily 
member) and NOXA. In fact Lambert et al. once reported that treatment of human 
sarcoma cell lines by PRIMA-1 induces multiple signaling pathways that 
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eventually converge on a common apoptosis route [112]. This interesting finding 
suggests that the drug could be a versatile agent in treating MM patients with or 




Figure 1.7. Chemical structures of small molecules PRIMA-1 and PRIMA-1Met. 
PRIMA-1Met is the methylated derivative of PRIMA-1 and is a more potent and 
active compound than its first generation counterpart [107].  
 
 
1.6 p53 family members 
p53 family members are a group of tumor suppressor proteins that consist 
of p53, together with two other similar but not identical proteins, p63 and p73 
(Fig. 1.8). Just like p53, p63 and p73 are highly evolutionarily conserved [113, 
114], with the presence of transactivation, DNA binding and tetramerization 
domains in their protein structure. Due to this structural homology, p63 and p73 
are suggested to have the same binding capacity to the p53 downstream targets 
[115]. However, these family members have additional extension at the C-
terminal that is not found in p53. The determination of the three-dimensional 
structure of the p73 C-terminus has shown that this region contains a sterile alpha 
motif (SAM), which is a protein-protein interaction domain [114] . This extension 
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is also the subject for alternative splicing for p73, giving rise to multiple isoforms . 
Critically, only the p73-TA-isoform (p73α) is functionally active in transcribing 
downstream targets in response to DNA damage. Other isoforms (β, γ, δ, ε, ζ) are 
often lacking in N-terminus. Figure 1.8 shows the structural organization of the 




Figure 1.8. Structural organization of p53 family members (p53, p63 and p73), 
together with different isoforms (α, β, γ, δ, ε, ζ). The percentage value indicated is 
the level of homology of the transactivation domain, DNA binding domain and 
tetramerization domain, respectively, relative to the p53’s. Dark grey shaded 
region is the SAM domain [115]. 
 
 
The homology shared by p53, p63 and p73 has suggested that the products 
of this gene family share similar functions as transcription factors. The highest 
homology was found at the DNA binding domain and this suggests that these 
family members are able to bind to the same DNA sequences and transactivate 
them. It has been reported that p73 is able to transactivate not all but only a 
certain set of p53 target genes, indicating that different genes respond differently 
to the family members [115].  
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Unlike its counterpart, p73 is not often mutated in human cancer. Only 
less than 1% of human cancer has been identified to harbor mutations in p73 
[115-118]. In fact, it is more common to have its gene silenced by promoter 
methylation and deletion of chromosome 1p36.1, a region on chromosome 1 at 
which TP73 resides in [113, 119, 120]. While the loss of p63 or p73 is associated 
with developmental defects and often implicated in solid epithelial cancers [114, 
118], p73 has seen a more frequent deregulation in blood cancer [116, 117, 119, 
121]. PCR-single-strand conformation polymorphism (SSCP) of p73 cDNAs in 
leukemia, lymphoma and myeloma cell lines and patient samples did not reveal 
any mutations at the hotspots (of p53), in samples expressing p73 [116]. On the 
other hand, methylation analysis of TP73 in samples with no p73 expression has 
shown that the CpG island on its 5’-UTR were hypermethylated and when they 
were treated with 5-Azacytidine, a potent global demethylator, p73 expression 
was rescued [116]. Subsequently, a few more reports highlighted the evidence of 
p73 hypermethylation in MGUS, which strongly suggests its role in myeloma’s 
disease progression [88, 121, 122]. Despite the existing reports on the loss of p73 
expression, there was no functional characterization of the protein in myeloma 








1.7 Endoplasmic reticulum stress pathway 
 
1.7.1 Endoplasmic reticulum (ER) stress 
Endoplasmic reticulum is an organelle in the cells that plays major roles in 
protein synthesis and folding, lipid and sterol biosynthesis, as well as free calcium 
storage. Proper protein folding into its functional three dimensional structure 
involves the assembly of multiple subunits of polypeptides and disulfide bond 
formation alongside glycosylation or lipidation processes [123]. The chaperone 
proteins within the ER are the main mediators for the correct folding and 
trafficking of newly synthesized proteins [123]. For instance, the HSP70 family 
member, GRP78/BiP is thought to bind to the unfolded proteins and then 
regulates the proper protein folding. Correctly assembled proteins are released 
from GRP78/BiP and are then transported to the Golgi apparatus. On the other 
hand, the unfolded and abnormally folded proteins remain bound to GRP78/BiP 
and are consequently retained within the ER [123].  
Accumulation of these unfolded proteins brings about stress in the ER and 
prolongation of this condition leads to the unfolded protein responses (UPR) and 
the triggering of ER stress pathway. The UPR serves dual function; it exists to 
alleviate damage associated with ER stress, however, if this is not possible, then it 
signals for cell death through apoptosis [124]. The UPR is an essential pathway 
for both normal and malignant plasma cells to maintain ER homeostasis. Owing 
to the disease pathology that involves excessive production of immunoglobulin, 
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MM cells bear a heavy load of unfolded proteins leading to ER stress and a 
persistent activation of UPR.  
 
1.7.2 ER stress pathway/ Unfolded Protein Responses (UPR) 
As shown in Figure 1.9, at the apex of UPR pathway are three trans-
membrane protein sensors, namely, inositol requiring kinase 1 (IRE1), double 
stranded RNA-activated protein kinase-like ER kinase (PERK) and the 
transcription factor activating transcription factor 6 (ATF6), all of which are 
bound by ER chaperone, GRP78/BiP. In response to the activation of UPR, 
unfolded proteins competes for GRP78 binding, causing the dissociation of these 
three sensor proteins from GRP78, thus activating them [125].  
Activated IRE1 removes 26 nucleotides intron from XBP1 mRNA [126, 
127]. Spliced XBP1 (XBP1s) is a transcription factor that gets translocated to the 
nucleus to transactivate a variety of UPR target genes, including ERdj4, p58IPK, 
DnaJ/Hsp40-like genes, ER degradation enhancer, mannosidasealpha-like 
(EDEM), human ER-associated DNAJ (HEDJ), proteindisulfideisomerase-P5 
(PDI-P5), and ribosome-associated membrane protein 4 (RAMP4) [125].  
PERK is a serine/threonine protein kinase. Upon activation, it 
phosphorylates eukaryotic initiation factor 2a (eIF2a) to halt further protein 
translation, resulting in a global repression of protein production. As a result, the 
overall protein load is lowered and the congestion in the ER is reduced. 
Concurrently, p-eIF2a promotes the translation of the activation transcription 
factor 4 (ATF4), which induce a set of genes involved in cell cycle and apoptotic 
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responses during ER stress including GADD34 and CHOP (C/EBP homologous 
protein) and NOXA [128-131].  
ATF6 is another component at the apex of the ER stress pathway and it 
has overlapping functions with both IRE1 and PERK arms. ATF6 is a 
transcription factor, which upon proteolytic activation in the Golgi complex, 
enters the nucleus to exert its function. XBP1 which is downstream of IRE1 is 
said to be a transcriptional target of ATF6, thus, it further enhances the pro-
survival response of the IRE1 arm [126, 128]. However, the ATF6 arm of the ER 
stress response eventually converge onto the PERK arm because ATF6, upon 
prolonged activation, also induces the transcription of CHOP (direct target of 
ATF4) which activates the apoptotic machinery [125, 126]. CHOP is the main 
mediator of ER stress-induced apoptosis and acts by transactivating GADD34 and 






Figure 1.9. Signaling pathways induced during UPR. ER stress causes the release 
of ATF6, PERK and IRE1 from chaperone protein GRP78, thus activating the 




1.7.3 ER stress pathway and multiple myeloma 
 ER stress in MM has been widely characterized due to the nature of the 
disease involving heavy production of immunoglobulins. In fact, a significant 
number of genes involved in protein homeostasis and UPR are frequently mutated 
in myeloma [15]. The ER stress pathway plays an essential role in maturation of 
B-cells and is hence of importance in the development of myeloma [132-134]. 
IRE1/XBP1 was found to be constitutively upregulated in MM to drive the 
differentiation and maturation of B-lymphocytes into antibody-secreting plasma 
cells.  This was evidenced by a report showing that chimera with XBP1 
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deficiency was unable to produce and secrete sufficient immunoglobulins of any 
isotype and easily succumb to infections due to low immunity [133, 135]. 
Furthermore, in IRE1α conditional knockout mice, the serum levels of IgM and 
IgG1 are reduced by half compared with the control mice [135]. These results 
indicate that IRE1/XBP1 is indispensable in myeloma cells maturation, 
highlighting the importance of activation of UPR in myeloma cells survival. In 
view of this, it is relevant to acknowledge that the baseline level of ER stress in 
MM cells is high in order to maintain a favorable condition for survival. In 
support of this statement, MM cells were found to inherently expressed ER 
chaperones GRP78/Bip and GRP94/gp96, both of which are bona fine ER stress 
markers [132]. There were surprisingly little reports about the functions of ATF6 
on MM. However, its pro-survival function was highlighted when specific 
knockdown of ATF6 resulted in a significant cell death [136], though its pro-
apoptotic properties in myeloma are yet to be proven. PERK’s role in mediating 
myeloma cell death was implicated when specific knockdown of this gene 
impeded the apoptotic response in myeloma cells [136].  
 
1.7.4 Therapeutics targeting ER stress pathway in multiple myeloma 
Given that myeloma cells are already subjected to ER stress at the baseline 
level, further perturbations to the protein homeostasis by exogenous stressors 
would yield massive UPR, thereby, tilting the pathway from pro-survival to pro-
apoptotic. Hence, this strategy is good to be exploited as a mechanism for anti-
myeloma therapeutics. In particular, the proteosome inhibitor, bortezomib 
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(velcade) has been shown to potently and selectively induce myeloma cell death 
by modulating the ER stress. Bortezomib was shown to suppress the activity of 
IRE1, hence impairing the generation of the pro-survival XBP1s [137]. The 
PERK pathway was also reported to be potently triggered in response to 
bortezomib treatment with the induction of eIF2a phosphorylation and subsequent 
expression of ATF4 and CHOP [132]. In fact, myeloma cells with a higher 
capacity for Ig production and secretion, hence higher ER stress, were reported to 
be more sensitive to the drugs and showed higher activation of ER stress markers 
[132, 138]. Despite the promising overall response rate to bortezomib in the clinic, 
there are still a number of patients who never responded to the drug and those that 















CHAPTER 2: GENERAL GAPS, OBJECTIVES AND HYPOTHESES 
 
In spite of an increasing understanding of the disease, MM remains 
incurable. There is a high frequency of relapse and most patients eventually 
become resistant to treatment [18]. This situation strongly points to the 
incomplete eradication of the clonal plasma cells. There is therefore an urgent 
need for more effective therapy for the disease. This study serves to study one of 
the factors behind drug resistance, i.e. the p53 pathway abnormalities and explore 
novel therapeutics that will hopefully contribute to the improvement of the 
patients’ outcome. 
Despite an extensive body of published work on p53, the knowledge of its 
functions and downstream signalling in MM is still not well understood. 
Monoallelic deletion of 17p13, harbouring the TP53 locus has been recognized as 
an independent prognostic marker for MM patients [19, 66, 69, 78, 139]. 
However, it remains largely unknown if TP53 is indeed the driver gene, as there 
are many other genes residing in this same region of the genome [19, 66, 67]. In 
this study, we aim to define the spectrum of abnormalities in the p53 pathway in 
relation to 17p13(del) in MM.  
It is unknown if one copy loss is enough to render compromised p53 
functionality, or if the endogenous dosage conferred by the remaining copy is 
sufficient for the p53 activity [19, 67]. In other words, this haploinsuffuciency 
property of p53 has yet to be characterized in myeloma.  This study uses 
genotoxic and non-genotoxic agents to perturb the p53 pathway for the 
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elucidation of the haploinsufficiency property of p53 in the monoallelic deletion 
cases. This approach also enables the concurrent interrogation of the critical 
value of TP53 in 17p13 region.  Given the prognostic relevance of 17p13 deletion, 
the hypothesis of this project is that TP53 is the critical gene and we seek to 
confirm this by delineating the minimal region of deletion on 17p13 in the 
publicly available clinical datasets and subsequently by conducting in vitro 
functional analysis to support the clinical data.  
Essentially, no reports have touched on the issue of whether the second 
p53 WT allele has already been suppressed by additional alternative mechanisms, 
leading to loss of heterozygosity.  Furthermore, it is not clear if the remaining 
wild type p53 copy in the cells is still functional and if the integrity of the 
downstream signalling is still intact. Therefore, it is imperative to study how p53 
pathway is affected under different p53 abnormalities, and how functionally 
crucial the loss of TP53 gene is, in relation to 17p13 deletion. Given the 
prevalence of p53 abnormalities in other malignancies and the multiple ways in 
which p53 function may be abrogated, we postulated that the p53 pathway may 
also be affected by other alternative mechanisms in MM, namely, MDM2 over-
expression or the abnormalities in the epigenetic regulation such as p14ARF 
silencing, aberrant p53 promoter methylation and miRNA deregulation. Therefore, 
it would be essential to probe for the mechanism behind the suppression of the 
remaining p53, if any, in order to aid in the establishment of more effective p53 
pathway activation.  
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In this project, HMCLs with a range of p53 status (WT/WT, WT/-, Mut, -
/-) are studied to observe the integrity of the p53 pathway in these cells. This 
approach would provide direct evidence for the association of the functionality of 
the p53 network with its respective genetic defects and enable specific correlation 
to their responsiveness to cancer therapies targeting and activating the p53 
pathway.  
In this regard, the incorporation of the well-established p53-reactivating 
drugs, nutlin-3 and PRIMA-1 into the project would provide an insight of how the 
rescue of the p53 pathway could contribute to the arrest of the MM development 
and progression. We seek to understand the responsiveness of HMCLs (especially 
the WT/-) to both nutlin-3 and PRIMA-1 and to dissect the mechanism behind 
their toxicity.  
Even though previous reports have documented the efficacy of nutlin-3 in 
killing myeloma cells [95], there is still nonetheless, an absence of knowledge of 
whether p53 hemizygous deleted-myeloma cells, which is a more clinically 
relevant study model, are responsive to this drug. Therefore, it is essential to 
further dissect the functional value of nutlin-3 in the patients with p53 hemizygous 
deletions. Besides gaining an understanding on the molecular mechanisms behind 
the anti-myeloma properties of nutlin-3, we would also like to establish the 
clinical applicability of nutlin-3 in this subset of patients. Herein, we hypothesize 
that the activity of nutlin-3 may defer depending on the presence, absence and 
type of p53 abnormalities.  
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Furthermore, the mutant-reactivating drug, PRIMA-1 which has shown 
potential activity in solid tumors [98, 100] and more recently in myeloma [111] 
also show exciting possibilities in this study. Even though p53 mutation was 
found in only approximately 3% of the patients, it accounts for poor prognosis in 
almost all of the cases. Thus, the employment of PRIMA-1 is deemed relevant in 
order to determine how this drug could rescue the actions of the mutant p53 and 
induce cytotoxicity. Since a recent report has hinted at a mutant-p53 independent 
mechanism [111], we figured that PRIMA-1 is targeting an alternative pathway 
other than p53 and this project aims to identify and decipher these possible 
pathways.  
Finally, with the p53 pathway abnormalities defined, we then seek to 
establish novel and more specific biomarkers for MM, especially for 17p13(del) 
cases. Subsequently, based on these biomarkers, we would then like to propose 
potential and feasible strategies to treat MM in a more specific and targeted 
manner. 
Because drug resistance is pervasive in the clinic, this project would serve 
as a plausible means for the identification of p53 dysfunction as well as for the 
development of novel biomarkers and therapeutics in myeloma to improve the 
outlook of the disease. A better understanding of cellular events and molecular 
pathway, at least the p53 pathway in this case, may shed some lights on future 




 In summary, the main objective and specific aims of the project are listed 
as follows: 
 
Main objective:  
To define the spectrum of abnormalities in the p53 pathway in 17p13(del) and 
associating them to their responses to novel p53 reactivating agents 
 
Specific aims: 
1. To elucidate the haphoinsufficiency of TP53 
2. To delineate the critical value of TP53 in 17p13  
3. To establish a novel and more specific biomarker for 17p13(del) cases 














CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Determination of 17p13 minimally deleted region 
Array-based comparative genomic hybridization (aCGH) data of Multiple 
Myeloma Research Consortium (MMRC) reference collection [15] (Gene 
Expression Omnibus (GEO) [2] ID: GSE26849) was segmented using circular 
binary segmentation algorithm [140] and each segment’s deletion status was 
determined based on the distribution of segments’ average log-ratio values. 
Specifically, segments with average log-ratio ≤ -0.2 and > -0.4 were designated as 
hemizygous deletion while segments with average log-ratio ≤ -0.4 were 
designated as homozygous deletion. The minimally deleted region was identified 
by aggregating all hemi- and homozygous deleted regions on chromosome 17 of 
the MMRC samples. Genes overlapping with this region were collected based on 
RefSeq genes with NCBI36/hg17 genome annotation [141]. 
 
3.2 Myeloma Cell culture 
HMCL with different known p53 status were employed into this study. Table 3.1 
shows the selected cell lines with their corresponding p53 status.  











WT: wild type; Mut: mutant; -: deletion 
Table 3.1. HMCLs employed into the study as our study models. 
 
All HMCLs were maintained in RPMI-1640 (Biowest Scientific, Ocala, 
FL, USA), supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 
100 ug/ml streptomycin and 2 mM glutamine. NCI-H929 was supplemented with 
additional growth factor beta-mecarptoethanol (Sigma Aldrich Inc., St Louis, MO, 
USA) to a final concentration of 0.05 mM. XG6 was grown in standard complete 
medium with 0.05 mM beta-mecarptoethanol and 2 nM of IL-6. All HMCLs were 
grown at 37oC in a CO2 incubator.  
 HCT116 and 293T cells were grown in standard DMEM (Biowest 
Scientific, Ocala, FL, USA) medium supplemented with 10% FBS and 1% 
Penicillin and Streptomycin. 
 Primary patient samples were obtained according to the protocol from 
International Review Board (IRB) and Declaration of Helsinki, with signed 
informed consent. Plasma cells were purified by using Ficoll density gradient 
centrifugation followed by incubation with CD138 beads. In vitro culturing of 
primary plasma cells were done in IMDM with 20% FBS, 1% L-glutamine, 1% 




3.3 Interphase fluorescent in situ hybridization (FISH) 
A large panel of HMCL has been characterized for various p53 abnormalities 
(Mayo Clinic, Arizona). 5 million cells of log phased-HMCLs were harvested for 
FISH analysis. To detect p53 deletion, a dye solution containing the mixture of 
both Spectrum Red-labeled DNA probes (specific for p53 locus on 17p13.1) and 
Spectrum Green-labeled probes (specific for centromere of chromosome 17), 
were hybridized onto the interphase chromosomes that have been prepared on a 
glass slide. Both probes were purchased from Vysis, Inc (Chicago, IL, USA). The 
slides were visualized under a fluorescence microscope and the cells were scored 
using Cytovision software (Leica Biosystem, Wetzlar, Germany). At least 100 
cells were scored and 10% was used as the cut-off value for the presence or 
absence of p53 deletion. 
 
3.4 Cell viability and proliferation assay 
Cell viability was assessed by MTS colorimetric assay. Cells were seeded and 
cultured in 96-well plates in 100uL complete medium at a density of 20 x 104 
cells/100 uL/ well. The cells were incubated with different concentration of drugs 
for 48 or 72 hours. Then MTS reagent (Promega, Madison, WI, USA) was added 
and the cells were further incubated for an additional 2 hours. Following 
incubation, the optical density of the cells was read with Tecan microplate reader 
at a wavelength of 490nm. Each experiment was made in triplicates, and the mean 
value was then calculated. The percentage of cell viability was normalized to the 
DMSO control.  
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3.5 Protein extraction and Western blot analysis 
The cells that have undergone treatment were harvested after indicated time point. 
Whole cell lysates were prepared from the cell pellet using RIPA lysis buffer 
(25mM Tris HCL (pH 7.6), 1% NP40, 5mM EDTA, 30mM Na pyrophosphate, 50 
mM NaF, 1 mM Na orthovanaolate, 1mM PMSF and 1 ug/ml), supplemented 
with protease inhibitor cocktail (Pierce, Waltham, MA, USA). Protein 
concentration was measured by Bradford protein quantification method (Bio-Rad, 
Hercules, CA, USA). Equal amount of protein extracts were resolved by SDS-
polyacrylamide gel electrophoresis and transferred to polyvinyl difluoride (PVDF) 
membrane (Bio-Rad, Hercules, CA, USA). The membranes were blocked with 5% 
milk in PBS with 0.1% Tween-20 (0.1% PBST) for 1 hour at room temperature.  
The membranes were then washed and probed with specific primary antibodies 
overnight at 4oC. The blots were then washed with PBST and incubated with the 
respective HRP-labeled secondary antibodies for another hour at room 
temperature before developing them using a chemiluminescent detection system 
(ECL, Santa Cruz, Dallas, TX, USA). The antibodies used are listed in Appendix 
table S1. 
 
3.6 Quantitative Real time PCR (qRT-PCR) 
The cells that have undergone treatment were harvested after indicated time point. 
Total RNA was isolated using the Qiagen RNeasy mini kit (Qiagen, Venlo, 
Limburg, Netherlands) and 1ug RNA was used for cDNA synthesis using 
iScript™ Reverse Transcription Supermix (Bio-rad, Hercules, CA, USA), 
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according to the manufacturer’s protocol. qRT-PCR was then performed with the 
cDNA samples by SYBR green method (BioRad iGreen Supermix). Specific 
primers (Appendix Table S2) were designed for the amplification of the required 
genes. The reaction was carried out with the initial denaturation step at 95oC for 
30 seconds, which is subsequently followed by 34 cycles of denaturation (95oC, 
30s), annealing (55oC, 30s), extension (72oC, 1 minute) and finally 1 cycle of 
final extension (72oC, 7 minutes). The fold change of the mRNA expression was 
calculated from the difference between treated and untreated cells, after 
normalization with endogenous control GAPDH (ddCt method). All reactions 
were carried out in triplicates. 
 
3.7 Apoptosis assay 
Annexin V- apoptosis assay was performed with ‘FITC Annexin V Apoptosis 
Detection Kit’ from BD Pharmingen, San Jose, CA, USA. Treated cells were 
harvested, washed twice with cold PBS and resuspended in 100 ul 1x binding 
buffer. The cells were then stained with 5 uL of FITC and 5uL of PI (exclusion 
dye) for 15 minutes at room temperature in the dark. Upon completion of staining, 
400 uL of binding buffer was added into the suspension and the samples were 
transferred to a 5 ml FACs tube through a filter mesh to generate singlet cells. 
Stained cells were analyzed with BD LSRII flow cytometer and the data was 
analyzed with BD FACs DIVA software.  Compensation of the assay was done 
with non-stained control, FITC- single stained control, PI- single stained control 
and FITC-PI- double stained control. The extent of apoptosis was quantified as 
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the percent annexin-V positive cells of treated relative to untreated cells. 
Percentage specific apoptosis was calculated by using the following equation:  
                 % specific apoptosis = (Test - Control) x 100 
          100 - Control 
 
3.8 Cell cycle analysis 
The DNA content in the cells was quantified using propidium iodide (PI) staining 
to gauge the cell cycle phase the cells are in. Treated cells were harvested and 
fixed in 70% ethanol overnight. The cells were then washed twice with cold PBS 
to rid off the remnants of ethanol. After that the cell pellets were resuspended in 
500uL PI (50 ug/ml) containing RNase (1 mg/ml), and were then incubated at 
room temperature for 15-30 minutes. Cell cycle profiles were determined by flow 
cytometric analysis with BD LSRII machine with BD FacsDIVA software. 
Compensation was done by having a no-dye control cells.  
 
3.9 Colony formation assay 
1 million cells of H929, XG6 and KMS18 were DMSO- and nutlin-3-treated for 
24 hours. The treated cells were then added to HSC-CFU medium (MACS 
Miltenyi Biotech, Bergisch Gladback, Germany) to a final concentration of 
2.0x105/ml. The mixture was vortexed vigorously to ensure that the cells were 
properly suspended. The tubes were left to sit for 10 minutes to allow air bubbles 
to rise. By using a sterile 3mL syringe with a 16 G MACS Blunt End Needle, 1 
mL of cell/medium suspension were transferred to a 12-well plate. Triplicates of 
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each treatment were done. The plate was then incubated in 37oC for 14 days, after 
which the colonies formed were observed and counted under a light microscope.  
 
3.10 TP53 shRNA lentiviral knockdown 
The lentiviral constructs expressing nontargeting (shCtrl) and p53 shRNAs 
(Sigma-Aldrich) were used. TRC-vectors were co-transfected into 293T cells 
using a calcium phosphate precipitation method with psPAX2 packaging plasmid, 
and pMD2.G, a plasmid encoding the lentivirus envelope. Supernatants 
containing pseudo-typed lentiviruses were collected at 48 and 72 hours and were 
used to infect NCI-H929. Three lentiviruses targeting p53 were screened to 
identify shRNA that optimally suppressed the p53. Equal titers of shCtrl, and sh-
p53 virus were used to infect cells.  After 48 hours of transfection, the cells were 
puromycin selected and immunoblotting of NCI-H929 lysates was used to gauge 
suppression of basal p53 level. Clone no. #21, which optimally suppressed p53, 
was used for subsequent experiments.  
 
3.11 Ectopic expression of p53 in JJN3 
JJN3 was chosen for the re-expression of p53 studies because it does not express 
any p53 at the mRNA and the protein level. pCMV-p53 vector was transfected 
into JJN3 at the titre of 0.1 ug, 0.25 ug and 0.5 ug using electroporation method 
(Neon Transfection System, Life Tech, Carlsbad, CA, USA). The transfection 
was conducted at 1200 V, 20 ms and 3 pulses. Positive transfected cells were 
selected using Puromycin for 48h before the cells were harvested for the p53 
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expression analysis via qPCR. Concurrently, the expression of p53 targets (p21, 
MDM2 and PUMA) was also analyzed to determine the transcriptional activities 
of the re-expressed p53 in the cells.  
 
3.12 Generation of p53 pathway gene signature 
Starting from a list of validated p53 targets that are not known to be affected by 
mutations in MM [28], we first examined correlations for all pairs using UAMS 
[142] and HOVON [143] gene expression profile datasets and selected three 
genes, PUMA, GADD45A and THBS1, that showed consistent correlation in both 
datasets for p53 pathway signature. For a sample in a dataset, then, the signature 
index was estimated as the median of log2-transformed median-normalized gene 
expression signal as follows: we normalized each gene’s expression signal using 
its median in the dataset, took logarithm (base 2) of the normalized value and 
calculated the median of resulting signal values of three member genes. 
Chromosomal instability (CIN) index was similarly estimated [144]. The 
correlation between p53 signature index and CIN index and the prognostic 
relevance of p53 signature was first assessed in above mentioned datasets and 
further validated in an independent APEX dataset [145]. 
 
3.13 Immunohistochemistry (IHC) 
The CD138/p53 and CD138/MDM2 double stains were carried out on 4-mm 
tissue sections containing the tissue microarrays (TMA) using the BondMax 
Autostainer (Leica Microsystems, Wetzlar, Germany) which utilizes the define 
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polymer technique. The slides were deparaffinized and hydrated.  Heat-induced 
epitope retrieval was performed for the first primary antibody (CD138) before the 
slides were incubated with CD138, followed by incubation in a post-primary 
polymer 3,3-diaminobenzidine (Bond Polymer Refine detection kit, Leica 
Microsystems, catalog no. DS9800) and chromogen 3,3-diaminobenzidine.  
Subsequently, heat-induced epitope retrieval was performed for the second 
primary antibody (p53 or MDM2) followed by incubation with polymer Refine 
Red (Leica Bond Polymer Refine Red kit DS9390) and fast red.  The nuclei were 
counterstained with hematoxylin and the slide dehydrated and cleared in xylene. 
Appropriate positive controls were used. The number of plasma cells expressing 
p53 or MDM2 were counted and scored as a percentage of the total CD138-
positive plasma cell population. The specific details of staining conditions are 
described in Appendix Table S4. 
 
3.14 Correlation of TP53 mRNA level with survival 
Using a publicly available gene expression profile data of 320 newly diagnosed 
MM patients participating in HOVON-65/GMMG-HD4 clinical trial (HOVON; 
GSE19784)(2), we assessed the correlation between TP53 mRNA level and 
patient survival. Expression level of TP53 was split into two groups using cutoffs 
in 0.49, 0.48, …, 0.05 percentile range and, for each cutoff value, survival 
difference between samples with TP53 expression below and above the cutoff 
was performed using Cox regression method. Hazard ratio (HR) and survival test 
p-value were collected for each cutoff and analyzed. 
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3.15 Methylation specific PCR (MSP) 
Cells treated with DMSO and 2.5 uM 5-Azacytidine for 24 hours were harvested 
and the genomic DNA was isolated with DNeasy Blood & Tissue Kit (Qiagen, 
Venlo, Limburg, Netherlands). Sodium bisulfate conversion of the genomic DNA 
was performed using the Epitect Bisulfite Kit (Qiagen, Venlo, Limburg, 
Netherlands), according to the manufacturer’s protocol. 2 ug of the isolated DNA 
was added to the bisulfite mix and the mixture was incubated in the thermal cycler 
according to the conditions stated in the protocol. The modified DNA was 
purified using MinElute PCR purification kit (Qiagen, Venlo, Limburg, 
Netherlands). PCR was carried out using 50 ng of DNA with methylated and 
unmethylated primers specific for the p53 promoter. The primer sequences 
(Appendix Table S3) and the cycling conditions have been reported previously 
[146]. PCR products were electrophoresed on 2% agarose gels stained with Gel-
red, and visualized under ultraviolet light. 
 
3.16 TP53 promoter methylation analysis from methylation array dataset  
Using a publicly available high-throughput methylation array dataset 
(GSE21304)[147] where samples of 161 MM patients from MRC Myeloma IX 
trial were assayed, we assessed the methylation status of TP53 promoter in 
myeloma patients. Deposited dataset contained β-values, the ratio between 
methylated signal compared with the sum of methylated and unmethylated signal, 
of 27,578 CpG dinucleotides. Though β = 0 represented completely unmethylated 
DNA and β = 1 completely methylated DNA, there was no clear cutoff to 
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determine the methylation status for each probe. Noticing that the peak 
corresponding to unmethylated DNA resided in β-values 0.2~0.25 range and 
effective leveling off of β-values beyond 0.2 in the dataset, we used β = 0.25 as 
the cutoff for probe methylation in this study. 
  
3.17 Determination of possible p53-regulating miRNAs 
Total RNAs, including small RNAs, were purified by miRNeasy Mini Kit 
(Qiagen). cDNAs were synthesized from total RNA using TaqMan MicroRNA 
Reverse Transcription Kit with gene-specific primers (Applied Biosystems). Real-
time RT-PCR quantification of miRNA expression was carried out using 
TaqManR MicroRNA Assays Kit (Applied Biosystems, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. The U6 snRNA was used as An 
endogenous control to normalize miRNA input in the qRT-PCR assay. 
To determine if miR-25 and miR-30d were important p53 regulators in the 
HMCLs with no p53 expression, specific anti-miR-25 and anti-miR-30d were 
ectopically introduced into the cells by using Dharmafect (D3) transfection 
reagent. The control (anti-miR with random sequence) and specific anti-miR 
treated cells were then harvested after indicated time point and Taqman 
MicroRNA Assay was again used to check the inhibition level of the miRNAs. 
Concurrently, p53 mRNA level was examined for the rescue effects of the anti-





3.18 Gene expression analysis 
DMSO-treated and PRIMA-1-treated KMS11 and JJN3 cells were harvested and 
total mRNA extraction was done by using the Qiagen RNeasy mini-kit (Qiagen 
Venlo, Limburg, Netherlands). The quality of the total RNA was checked by 
using the Nanodrop 1000 to ensure that the 260/280 and 260/230 ratio was at least 
above 2.0 to rule out any protein or organic contaminations in the samples. Gene 
profiling was done on Affymetrix platform (ExonExprChip.HuGene-1_0-st-
v1_na31_hg19_2010-09-03) according to the manufacturer’s protocol. 
Differentially expressed genes of at least 2 folds between DMSO- treated and 
PRIMA-1- treated cells were extracted. Validation of the genes was done by Real-
time-PCR.  Gene Ontology (GO) pathway analysis involving the genes that were 
differentially expressed were conducted using Database for Annotation, 
Visualization and Integrated Discovery (DAVID, v6.7) to identify the pathways 
that were significantly enriched upon PRIMA-1 treatment. 
 
3.19 Detection of XBP1 splicing 
2 million cells were treated with PRIMA-1 or tunicamycin and total RNA was 
isolated using the Qiagen RNeasy mini kit. 1 ug RNA was used for cDNA 
synthesis using iScript™ Reverse Transcription Supermix (Bio-rad), according to 
the manufacturer’s protocol. To evaluate relative expression levels of 
XBP1u/XBP1s, semi-quantitative RT-PCR analysis was performed using PCR 
SuperMix (Invitrogen). PCR products were visualized on a 2.5% agarose gel 




Reverse: 5’- GGGTCCAAGTTGTCCAGAATGC-3’ 
 
 3.20 Luciferase assay 
JJN3 and KMS11 were transfected with Cignal ERSE reporter (Qiagen, Venlo, 
Limburg, Netherlands), a luciferase reporter plasmid which has an ER stress 
response element (CCAAT(N9)CCACG) upstream of the firefly luciferase gene 
(Fig. 3.1). Transfection was done by electroporation method (Neon Transfection, 
Life Tech, Carlsbad, CA, USA). 24 hours after the transfection, the cells were 
washed with PBS and were then treated with DMSO, PRIMA-1 or tunicamycin 
(positive control) for another 16 hours, after which the cells were harvested and 
were analyzed with the Dual Luciferase system (Promega, Madison, WI, USA). 
Renilla luciferase construct acts as an internal control for normalizing transfection 
efficiencies (Fig. 3.1). Data was presented as ratios, with the activity of cells 




Figure 3.1. Luciferase reporter system for the detection of ATF6 activity. ERSE, 
which is bound by ATF6 upon ER stress induction is located upstream of 





3.21 Reactive Oxidative Stress (ROS) detection assay 
1 million cells were DMSO- or PRIMA-1-treated for 6 hours.  The cells were then 
harvested and washed with PBS twice. After that, 200 uL of CM-H2DCFDA (an 
indicator for ROS) conjugated with FITC dye (Life Tech, Carlsbad, CA, USA) 
was added into the cells to a final concentration of 2.5 uM, and the solution was 
incubated at 37oC for 30 minutes. Following that, the dye was washed away twice 
with PBS. After the final wash, the cells were re-suspended in PBS and were 
transferred to the FACS tube through filter mesh. ROS-positive cells were 
quantified with BD FACs DIVA software. 
 
3.22 Statistical analysis 
Statistical significance between different treatment groups was done with 
Independent T-test, assuming normal distribution of mean. Survival analysis was 
done by using the Kaplan-Meier function, and difference in survival was 
compared using the log-rank test. IC50 of nutlin- and PRIMA-1-treated cells and 
combination index (CI value) for the combination drug treatment (PRIMA-1 and 
bortezomib) were analyzed using CompuSyn software (Combosyn, Inc, Paramus, 
NJ, USA) by Chou-Talalay method. CI of 1 indicates an additive effects, CI of 







CHAPTER 4: RESULTS 
 
4.1 Haploinsufficiency of p53 in multiple myeloma 
As monoallelic deletion of p53 has been established as an independent 
prognostic marker in MM, it has remained elusive as to whether the remaining 
single allele of p53 is still functional or not and if its dosage is enough to exert its 
anti-tumorigenesis effects. In other words, the haploinsuffuciency property of p53 
has yet to be characterized in myeloma. The following section describes about 
how one copy loss of p53 is enough to abrogate the p53 activity either partially or 
completely, and essentially highlights its critical value as a tumor suppressor gene 
in the 17p13 region. 
 
4.1.1 TP53 was located in the minimally deleted region of 17p13!
In order to identify the minimally deleted region in 17p13 chromosome, 
the publicly available myeloma dataset from MMRC was analyzed. It was found 
that 10% of the 254 samples have 17p13 deletion (Fig. 4.1A). The majority of the 
17p13 deletion cases involved a large part of the 17p arm. No homozygous 
deletions were noted (Fig. 4.1A). When gene mapping was pursued, three 
individual cases have areas of smaller interstitial loss. The minimally deleted 
region in these samples was found to encompass the area between 7.5 Mbp and 
8.2 Mbp (0.6 Mbp) (Fig. 4.1B) and contained 32 genes, including TP53 itself. The 








Figure 4.1. Analysis of the MM cases in MMRC dataset. (A) aCGH analysis of 
the TP53 allelic status. Homozygous Deletion: double copy loss, Hemizygous 
Deletion: one copy loss (B) Gene mapping of 17p13(del) cases. The minimal 








4.1.2 Genetic characterization of human myeloma cell lines (HMCLs) 
In relation to the above finding, we hypothesized that for TP53 to be the 
critical gene within 17p13, it should act as a haploinsufficient tumor suppressor 
gene in promoting disease progression.To confirm this hypothesis, we performed 
a series of functional analyses by using human myeloma cell lines as our study 
models.  
Based on available database (Mayoclinic, Arizona USA) documenting the 
p53 mutation status (from Sanger sequencing) and copy number (from array CGH) 
status of the p53 locus on chromosome 17p13 in HMCLs, we randomly selected a 
few cell lines to be used in this study (Table 3.1, materials and methods).  In line 
with the main study objective in identifying the functional status of single copy of 
p53 in WT/- cells, FISH was performed to validate the TP53 allelic status in all 
the wild type cell lines prior to all downstream studies. Due to the slow-growing, 
hypo-proliferative nature of myeloma cells, interphase rather than metaphase 
FISH was the choice of analysis [7].   
Figure 4.2 shows the representative FISH diagrams of each HMCL tested 
and the composition of cells with different p53 content. Chromosome 17 
centromere (green signal) was concurrently detected with TP53 allele (red signal) 
to identify small deletion of the p53 gene versus loss of the whole chromosome. 
As shown in Fig. 4.2, the HMCL cells demonstrated mainly tetraploidy of 
chromosome 17 (four green signals), which is common in immortal cell lines. 
Based on the percentage of p53-positive cells detected, the HMCLs were labeled 
with their respective p53 copy status. As MM is a highly heterogenous disease 
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even within the same clones, it is largely impossible to obtain a cell line that has a 
complete or 100%  diploid p53 status. Our approach was to select the cell line that 
has the highest percentage cells with diploid WT p53 to best represent the 
WT/WT status. In a tetraploid cell, p53 deletion is indicated if red signals were 
detected to be less than four. Hence, we labeled NCI-H929 and MM.1s to be of 
WT/WT status, whereas other WT cells, XG6, KMS18 and JJN3, which showed 
p53 deletion, were labeled as WT/-. 
 
 



























Figure 4.2. FISH analysis of the HMCLs used for this study. Green probe 
represents chromosome 17 centromere; red represents TP53. (G:green, R:red). 
The cells were counterstained with DAPI for nuclear staining.  
 
 
4.1.3 Different array of p53 expression pattern was associated with different 
p53 status 
As almost all deletion of the p53 locus is monoallelelic, and the concurrent 
mutation of the remaining allele is rare [19, 65], we hypothesized that p53 is a 
haploinsufficient tumor suppressor in myeloma. Therefore, it is necessary to 
investigate how p53 copy loss may affect the p53 dosage endogenously. In order 
to gauge the p53 basal activity in the selected HMCLs, endogenous p53 mRNA 
and protein expression levels were investigated.  
The HMCLs displayed a different array of p53 mRNA and protein 
expression corresponding to their respective p53 status (Fig. 4.3A and 4.3B). 
Normalizing to WT/WT (NCI-H929) cells, the mutant cells RPMI-8226 and 
U266 showed constitutively high expression of p53 [44, 48], p53-/- KMS11 was 








 On the other hand, the HMCLs of interest, the WT/- cells (XG6, KMS18 
and JJN3) showed general reduction of p53 dosage compared to WT/WT cells. 
Interestingly, despite sharing the same genotype, the WT/- cells have differential 
expression pattern of p53 amongst them. XG6 has the highest basal p53 mRNA 
and protein, albeit more than 50% lower mRNA expression, and at least three 
folds lower protein expression when compared to NCI-H929 (WT/WT). Baseline 
p53 expression in KMS18 was very low at the transcript level and undetectable at 
the protein level. On the other hand, JJN3 showed complete absence of p53 
mRNA and protein. These results indicated that hemizygous deletion of TP53 is 
associated with the reduction of cellular p53 dosage and its dosage reduction can 
affect its basal mRNA and protein expression, suggesting p53 haploinsufficiency 
[148]. Despite the existence of one non-mutant p53 allele, KMS18 and JJN3 had 
very low or no mRNA and protein expression, indicating that in these cells other 
mechanisms may actually be involved in silencing the remaining allele.  
 






                 
 
Figure 4.3. HMCLs with different p53 status displayed an array of basal p53 
mRNA (A) and protein (B) expressions. HMCLs were incubated under minimum-
stressed conditions. WT/- cells generally have lower p53 expression as compared 
to WT/WT and mutant cells.  
 
 
4.1.4 WT/- cells were more resistant to drug-induced-apoptosis as compared to 
WT/WT cells 
Cellular stress activates the p53 pathway leading to the induction of 
apoptosis and cell cycle arrest. Thus, the effects of p53 genotype and gene dosage 
on these p53 physiological functions are best studied by inducing stress response. 
Etoposide is a topoisomerase II inhibitor which has been used in the treatment of 
a wide range of cancers including MM. It induces DNA double strand breaks to 
the cells, thereby triggering the activation of p53 pathway via a genotoxic stress 
mechanism [149, 150]. We therefore use etoposide to treat the panel of HMCLs 
and the physiological response of the cells with different p53 status was 
investigated. PARP or poly (ADP-ribose) cleavage assay and annexin-V labeling 
were used to measure the extent of apoptosis in the cells treated for 24 hours.  
Of relevance, NCI-H929 (WT/WT) cells displayed an efficient apoptosis 
response with the highest amount of cleaved PARP and annexin-V positive cells 




expectedly showed a negligible amount of cell death, a phenotype attributable to 
their impaired p53 responses [24, 44]. Not surprisingly, the p53-deficient-KMS11 
also recorded a minimal apoptotic response. Thereafter, the WT/WT NCI-H929 
was used as a positive control and the p53-mutant and p53-/- HMCLs were used 
as negative controls.  
Intriguingly, the WT/- XG6, which has detectable p53 protein at baseline 
(Fig. 4.3), exhibited an apoptosis response at a much lower degree (~11%) than in 
NCI-H929 (WT/WT) (~20%). In contrast, the remaining WT/- cells with very low 
or complete absence of basal p53 (KMS18 and JJN3) depicted etoposide 
resistance as there was no increased in c-PARP (Fig. 4.4A) and recorded only a 
minute number of annexin-V-positive cells (Fig. 4.4B) upon drug treatment.  
Even though there was a differential p53 functional response in the WT/- cells, 
these data strongly indicate that their response rate to genotoxic stress was already 
compromised when one allele is lost.  
As mentioned in the Chapter 1, nutlin-3, which is an MDM2 inhibitor, was 
developed as a non-genotoxic activator of WT p53. In order to investigate its 
efficacy in WT/- MM cells, the ability to reactivate the p53 pathway in the 
presence of only single copy of p53, we treated these HMCLs with nutlin-3. 
MM.1s (WT/WT) was used as a positive control, as it has been shown to have 
high sensitivity to nutlin-3 [95].  
As depicted in Fig. 4.4C, the viability of MM.1s, NCI-H929 and XG6, all 
of which harbor WT p53, showed a sharp decline with nutlin-3 treatment, 
displaying less than 20% cell viability at 10uM drug concentration. However, 
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there was no effect in the p53 mutant and -/- cells. This is consistent with previous 
reports on the requirement for WT p53 in nutlin’s efficacy. Nevertheless, it is 
important to note that the IC50 of XG6 (WT/-) (3.12 uM) was much higher than 
that of WT/WT (1.14 uM in NCI-H929 and 1.52 uM in MM.1s) (Fig. 4.4C). Both 
WT/- cells, KMS18 and JJN3, which have minimal endogenous p53 (Fig. 4.3), 
were refractory to the treatment.  
In parallel to the MTS results, nutlin-3 treatment caused a marked increase 
in apoptosis in both NCI-H929 (~70%) and XG6 (~40%) (Fig. 4.4D). In contrast, 
the WT/- cell lines with low or zero basal p53 expression (KMS18 and JJN3) 
were resistant to apoptosis induction, as were the negative controls U266, RPMI-
8226 and KMS11 (Fig. 4.4D). Importantly, again, the increase in annexin-V 
positive cells in XG6 (WT/-) was significantly lower than in NCI-H929 (WT/WT) 
after treatment, indicating a sub-optimal activity of p53 in the WT/- cells.  
In addition, cell cycle profiling was also performed to look at the effects of 
the loss of p53 on this phenotype in response to the drugs. This analysis revealed 
markedly increased sub-G1 cell population, which is a hallmark of apoptosis, 
again, only in nutlin treated- NCI-H929 and -XG6 (and not other cell lines tested, 
data not shown), but to a much lower extent in XG6 (Fig. 4.4E).  
Collectively, these data suggests that a reduction in p53 gene dosage and 
protein level impairs growth inhibition and defective apoptosis in response to 
genotoxic and non-genotoxic stress, emphasizing the haploinsufficient property 






















Figure 4.4. WT/- cells were more resistant to genotoxic and non-genotoxic 
drug treatment than WT/WT cells. (A) PARP analysis of DMSO and etoposide 
(5 uM) treated cells after 24 hours treatment. 1: DMSO, 2: Etoposide 5 uM (B) 
Annexin-v assay on cells treated with DMSO and 5 uM etoposide for 24 hours. 
(C) Cell viability was analyzed by MTS assay after the cells were nutlin-3 treated 
for 72 hours. Dotted lines represent the IC50 value of the indicated cell line. (D) 
Annexin-V positivity was measured by flow cytometry after the cells were treated 
with nutlin-3 for 48 hours. Each bar represents mean ±SD, *p<0.05, ** p<0.0001. 
(E) Cell cycle analysis of 48 hours DMSO and nutlin-treated NCI-H929 (WT/WT) 





4.1.5 WT/- cells have non-functional p53 signaling pathway  
Next, we investigated if the partial (XG6) or absolute resistance (KMS18 
and JJN3) towards genotoxic or non-genotoxic stress-induced apoptosis was due 
to the attenuation of the downstream p53 signaling in these WT/- cells. In this 
instance, HMCLs were treated with nutlin-3 and etoposide and p53’s function as a 
transcription factor was assessed by checking for the expression of p53 direct 
targets.  
Upon nutlin-3 treatment, a differential expression profile of downstream 
proteins was observed in relation to their respective p53 status. WT/WT (NCI-
H929 and MM.1s) cells showed normal functional p53 responses as evidenced by 
the marked upregulation of total p53 and its targets MDM2, p21, PUMA and 
NOXA (Fig. 4.5A), indicating that the intact p53 pathway accounted for the 
nutlin-induced toxicity observed in these cells (Fig. 4.4). As expected, the 
negative control mutant cells (RPMI-8226 and U266) with their defective 
transcriptional activities, showed a complete abolishment of downstream p53 
signaling, as did p53–deficient-KMS11, thereby leading to zero response towards 
nutlin-3.  
Interestingly, differential p53 pathway response was seen amongst the 
WT/- cells. XG6, which has a relatively higher basal p53 level, showed an intact 
p53 pathway, as demonstrated by the protein expression profile of the similar 
trend as the WT/WT NCI-H929’s. On the other hand, in cells with low or zero 
basal p53 (KMS18 and JJN3), an abrogated p53 signaling was observed, whereby 
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there was an absence of expression of p21 and MDM2, and no change in the 
PUMA and NOXA protein expression level, upon nutlin-3 treatment.  
In fact, when the genotoxic agent, etoposide was used to treat the same set 
of HMCLs, a similar protein expression profile was depicted (Appendix Fig. S1). 
Thus, these results highlighted the importance of wild type p53 basal expression 
and its functional transcriptional activity in retaining the integrity of its 
downstream pathway and triggering drug-induced apoptosis.  
To rule out possible dilution of p53 expression in the total protein lysate of 
WT/- cells by whole cell lysis technique, nucleus/ cytoplasmic fractionization was 
performed. Besides having to obtain a more concentrated protein in different 
cellular compartments, this technique also allows the checking for protein 
localization especially it is known that p53 is a predominantly nuclear protein. 
From Figure 4.5B, it was observed that p53 was localized in both nucleus and 
cytoplasm in NCI-H929 and XG6 in the untreated state. Upon nutlin-3 exposure, 
the p53 in both fractions was upregulated in both cell lines, rendering an activated 
downstream response as manifested by the increased cytoplasmic and nuclear p21 
and MDM2. WT p53 in both the nuclear and cytoplasmic fraction was abundant 
and sufficient, thus, nutlin-3 stimulation causes an excitation of its downstream 
signaling. Nevertheless, we saw that the p53 pathway activity was actually less 
intense in XG6 (WT/-) than NCI-H929 (WT/WT). Furthermore, it is noted that 
KMS18 does actually have a minute amount of nuclear p53 protein, 
corresponding to its low basal mRNA level (Fig. 4.3); however, its low intensity 
was proven to be inadequate to constitute a functional p53 pathway as 
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demonstrated by the absence of p21 and MDM2 expression, once again reflecting 
the critical role of basal p53 expression and supporting our haploinsufficiency 
hypothesis. On the other hand, JJN3 showed complete absence of p53 in both its 
cytoplasmic and nuclear extract, indicating that complete silencing of its 
remaining gene has already taken place.  
Quantitative real-time PCR was also performed to check the 
transcriptional activity of p53 at the mRNA level. Consistent with Western blot 
analysis, p53 transcriptional activity was seen only in XG6 and NCI-H929 and 
not in other cell lines with non-functional p53 (Fig. 4.5C). Importantly however, 
the fold increase of the transcripts in XG6 (WT/-), was found to be generally 
lower than that in NCI-H929 (WT/WT).  
Therefore, these results showed that there is a reduction of p53 
transcriptional activity in the presence of hemizygous loss, a condition typical for 
haploinsufficiency, and that the p53 dosage is crucial in determining functionality 












Figure 4.5. WT/- cells have impaired p53 signaling pathway. (A) HMCLs 
were treated for 16 hours and cell lysate were prepared for Western Blot analysis. 
WT/WT (NCI-H929 and MM.1s) and XG6 (WT/-) showed functionally active 
p53 pathway. Other WT/- cells showed complete abolishment of the pathway. (1: 
Nutlin 0 uM, 2: Nutlin 2.5 uM, 3: Nutlin 5 uM, 4: Nutlin 10 uM). (B) p53 nuclear/ 
cytoplasmic fractionization of DMSO and 2.5 uM nutlin-treated-HMCLs for 16 
hours. (C) HMCLs were treated for 8 hours followed by total RNA extraction and 
cDNA synthesis. The samples were subjected to real-Time PCR analysis for p53 
downstream targets MDM2, p21, PUMA and NOXA. p53 mutant and p53 -/- 







4.1.6 Colony formation was inhibited in WT/WT cells but WT/- cells retain its 
colony formation ability 
Myeloma cells are heavily subjected to interleukin nourishments in the 
bone marrow microenvironment, which facilitate its clonogenic growth, a 
mechanism that is important in promoting the progression of the disease. As 
potent as it is in bringing about WT-p53-dependent apoptosis, nutlin’s role in 
inhibiting the clonogenic growth of MM cells has never been characterized. Thus, 
to further elucidate the efficacy and mechanism of nutlin-3 as anti-myeloma agent, 
as well as to interrogate how one copy loss of p53 could affect this ability in the 
WT/- cells, the colony formation assay was conducted.  
NCI-H929 (WT/WT), XG6 (WT/-) and KMS18 (WT/-) were treated with 
DMSO and nutlin-3 for 24 hours and the cells were then incubated in the 
hematopoietic stem cell-methylcellulose-based media for 14 days to observe the 
colony formation process. As shown in Figure 4.6A, nutlin-3 treatment saw an 
almost complete suppression, with a five-fold reduction in the number of colonies 
formed in NCI-H929 (WT/WT). XG6 noted only a two-fold decrease in the 
colonies number whereas KMS18 showed non-significant suppression in its 
colony formation ability upon nutlin-3 treatment. Figure 4.6B shows 
representative pictures of the cell colonies formed in the wells of respective 
HMCLs. 
This data reflects the possible function of p53 in modulating the colony 
forming ability of myeloma cells in a haploinsufficiency manner. Furthermore, it 






Figure 4.6. Colony formation assay in WT/WT (NCI-H929) and WT/- (XG6 
and KMS18) cells. HMCLs were treated with DMSO and 2.5 uM for 24 hours 
and were incubated in HSC-Methocult CFU medium for 14 days. (A) 
Quantification of the colonies formed in the HMCLs. (B) Representative pictures 




4.1.7 Knock-down and over-expression studies confirmed the 
haploinsufficiency of TP53 in MM 
Given that baseline p53 dosage was shown to be an important determinant 
of the integrity of the p53 pathway, further validation on the haploinsufficiency of 
TP53 was performed by knocking down p53 in NCI-H929 (WT/WT). This 
experiment is important in order to rule out possible biases that could arise from 
different cell line comparison harboring differential genetic background. 
As shown in Fig. 4.7A, among the three independent lentiviral- shRNAs 




results, whereby it was able to suppress the p53 expression level by up to ~90% as 
compared to non-targeting shRNA. Thereafter, NCI-H929-shp53-#21 stable cell 
line was used for subsequent studies.  
The critical role of p53 gene dosage and its basal expression level was 
further verified by significantly higher cell viability in NCI-H929-shp53 cells as 
compared to its isogenic control cells when treated with an increasing 
concentration of nutlin-3 (Fig. 4.7B). Furthermore, p53 transcriptional activity in 
NCI-H929-shp53 cells was severely attenuated as manifested by an almost zero 
expression of both MDM2 and p21, whereas the downstream response was 
completely retained in the NCI-H929-shCtrl cells (Fig. 4.7C). Knock-down of 
p53 also obliterated the cells’ ability to undergo apoptosis with the virtual absence 
of PARP cleavage upon nutlin-3 treatment (Fig. 4.7D). In order to exclude the 
possible cell line specific effects in NCI-H929, similar p53 knockdown 
experiment was performed in another WT/WT HMCL, MM.1s. Consistently, the 
results from NCI-H929 knockdown were replicated when p53 expression was 
depleted in MM.1s with specific p53 siRNA, suggesting that the effects observed 
in NCI-H929 was not cell line specific (Fig. 4.7E). This provides further evidence 
that p53 signaling and response in myeloma is dependent on p53 gene dosage and 
that the loss of basal p53 expression does impair its downstream tumor 
suppressive functions.  
 To further demonstrate this, the converse experiment was then performed. 
p53 was ectopically introduced into JJN3, a HMCL that has complete absence of 
p53 mRNA and protein. Transfection of 0.25ug of pCMV-p53WT was enough to 
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upregulate p53 to approximately 40 folds of mRNA and 4-5 folds of protein (Fig. 
4.7F and 4.7G). Over-expression of p53 strikingly contributed to the reactivation 
of the p53 pathway with increased expression of p21, MDM2 and PUMA at both 
the protein and mRNA level (Fig. 4.7G and 4.7H). Hence, these experiments 
collectively establish the functional significance of TP53 haploinsufficiency in 






















Figure 4.7.  TP53 is haploinsufficient in myeloma. (A) Up to 90% of 
knockdown was achieved by p53 shRNA clone #21. Cells from this clone were 
used thereafter as an isogenic partner for NCI-H929-shCtrl. (B) Cell viability of 
NCI-H929-shCtrl and NCI-H929-shp53 were analyzed by MTS assay after 
treatment with nutlin-3 for 72 hours; *p<0.01, **p<0.0001. (C) NCI-H929 
isogenic cells were nutlin-treated for 16 hours and were harvested for Western 
Blot analysis. (1: Nutlin 0 uM, 2: Nutlin 2.5 uM). (D) PARP cleavage analysis 
was performed after NCI-H929 isogenic cells were treated with nutlin-3 for 24 
hours. (E) MM.1s-sictrl and MM.1s-sip53 cells were treated with nutlin-3 for 16 
hours and were harvested for Western Blot analysis. (F&G) Overexpression of 
TP53 into JJN3 was confirmed by qPCR (F) and Western blot (G). (H) 






4.1.8 Clinical impact of p53 on patient survival 
The current in vitro data has shown sufficient and solid evidence of TP53 
being a haploinsufficient gene in MM. Even though previous reports have 
provided a strong ground of the importance of 17p13 deletions as an independent 
prognostic marker, changes in the protein levels of p53 and its impacts are not 
well studied in MM. Limited knowledge about this issue was merely addressed by 
only two previous studies demonstrating an association of p53 deletion with 
intense nuclear p53 staining in primary samples and adverse prognostic outcome, 
but the mutational status of TP53 in the samples was not specified [20, 151].  
Following suit, we would also like to establish the clinical relevance of 
our in vitro observations, mainly on the importance of basal p53 expression in 
conferring an intact p53 signaling and a functional downstream phenotype. 
Immunohistochemistry (IHC) using specific antibodies against p53 was 
performed on a tissue microarray (TMA) of MM samples (n=90). The 
representative IHC results for the double staining of CD138/p53 are shown in Fig. 
4.8A and 4.8B. We observed an increase of nuclear p53 immuno-reactivity with 
disease stage (Fig. 4.8C) (p=0.0012), indicating the importance of p53 
abnormalities in disease progression, an observation consistent with previous 
reports [19, 69, 74]. However, we did not see any association between p53 protein 
expressions with survival (Fig. 4.8D).  
In contrast, we found that p53 expression at the mRNA level was 
clinically significant. When we analyzed the MMRC dataset, we found strong 
correlation between TP53 copy number loss with low p53 mRNA expression (Fig. 
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4.8E). Importantly, the prognostic importance of p53 mRNA expression was 
further established when we identified a significant difference of survival between 
patients with top 90% and those with bottom 10% of p53 mRNA expression (Fig. 
4.8F). Essentially, this also means that our results from functional in vitro analysis 
also corroborate the trend from these clinical findings obtained from two 


















Figure 4.8. Clinical impact of p53 expression on patient survival. (A) Double 
staining CD138/p53 was done on bone marrow sections; CD138 (red-membrane) 
and p53 (brown-nuclear). A case with p53 expression in more than 95% of the 
CD138 positive plasma cells (original magnification x600) (B) A case with p53 
expression in less than 5% of the CD138 positive plasma cells (original 
magnification x600) (C) Number of cases with positive p53 expression in 
different disease stages. (D) Kaplan-Meier analysis (20% cut off value) of newly 
diagnosed cases identified no association of low p53 protein expression with poor 
survival. (E) Correlation of p53 copy number with p53 mRNA expression level in 
MMRC dataset (F) Example survival curve at cutoff 10% shows that low p53 








4.2 Negative regulation of p53 
 In section 4.1, our results indicated that not all WT/- cells contain the 
same endogenous dosage of p53 (Fig. 4.3). Despite still bearing one WT p53 
allele, the p53 protein expression of KMS18 and JJN3 was absent at its protein 
level. These observations point to the possibility that other mechanisms may be 
involved in suppressing or silencing the expression of remaining allele in these 
cells.  
 
4.2.1 Endogenous MDM2 expression levels 
One of the main mechanisms inhibiting p53 function in cancer is the 
amplification or over-expression of its negative regulator MDM2. As 
amplification and over-expression of MDM2 have been reported in the clinical 
samples of advanced stage of MM (PCL) [73, 79, 80], we investigated if this 
could be a mechanism of suppressing the remaining copy of p53 in cases with 
mono-allelic loss of 17p13.  
Basal level of MDM2 mRNA and protein were checked in the WT/- cells 
(XG6, KMS18 and JJN3). After normalizing to normal non-cancer cells, XG6 
displayed the highest endogenous MDM2 expression at both the protein and 
mRNA level (Fig. 4.9A and 4.9B). In contrast, KMS18 had a MDM2 expression 
level comparable to that of the normal samples, whereas JJN3 had zero MDM2 
expression.  In fact, at the mRNA level, the same trend was also observed. This 
result suggests that MDM2 could be the factor that is limiting the protein 
expression and functional activity p53 in XG6, but not in KMS18 and JJN3.  
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In view of the above finding, it is relevant to assume that abnormalities in 
p53 pathways may not be only limited to 17p13 deletion or p53 mutations in MM. 
Changes in the protein levels of key regulatory proteins such as MDM2 may be of 
paramount importance too. In order to extend the validity of this in vitro data to 
clinical samples, survival analysis was performed on TMA samples (same TMA 
platform used for p53 expression in Fig. 4.8) that was double stained for both 
CD138 and MDM2 to investigate the association of MDM2 level with the MM 
patients’ outcome (Fig. 4.9C and 4.9D).  
Indeed, newly diagnosed MM with high MDM2 expression (positive 
staining in 10% or more of plasma cells) is associated with significantly worse 
prognosis (Fig. 4.9E). This finding further validates the clinical relevance of 
MDM2 over-expression in MM and that poor prognosis in this subset of patient 
may be attributable to the suppression of functional p53 by the overexpressed 




















Figure 4.9. Impact of MDM2 expression on MM cells. HMCLs were incubated 
under non-stressed conditions and mRNA and protein were extracted. Basal (A) 
mRNA and (B) protein level of MDM2 in HMCLs with different p53 status. (C) 
MDM2 expression present in 10-20% of CD138 positive plasma cells (see arrows) 
(CD138/MDM2 double stain, original magnification x600) (D) MDM2 
expression present in less than 5% of CD138 positive plasma cells (MDM2/p53 
double stain, original magnification x600) (E) Kaplan-Meier analysis of newly 
diagnosed cases identified the association of high MDM2 expression with poor 










4.2.2 Endogenous MDM4 expression levels 
As amplification of chromosome 1q, harbouring MDM4 gene has been 
reported to be prognostically important in MM [2, 81], we investigated the 
potential role MDM4, another negative regulator of WT p53, in contributing to 
the attenuation of the p53 activity in WT/- cells. This is particularly important 
given its independent role in regulating p53 activity and its secondary role in 
enhancing and supporting the E3 ubiquitin ligase activity of MDM2.  
The basal expression of MDM4 was examined in the same set of cell lines. 
Despite having higher MDM4 transcript levels (Fig. 4.10B), all the WT/- cells, 
namely XG6, KMS18 and JJN3, have lower protein expression compared to 
normal cells (Fig. 4.10A). As MDM4 protein instead of its mRNA is needed to 
execute its suppressive function on p53, our results suggest that MDM4 is not one 





Figure 4.10. Basal MDM4 expression in HMCLs. HMCLs were incubated 
under non-stressed conditions and was extracted for mRNA and protein. Basal 
level of MDM4 (A) mRNA and (B) protein in HMCLs with different p53 status. 





 4.2.3 Global demethylation agent induces re-expression of p53 
Given that MDM2 and MDM4 regulation of p53 in both KMS18 and JJN3 
at the protein level has already been ruled out (Section 4.2.1 and 4.2.2) and that 
the p53 expression of these cells is either very low or completely absent at the 
mRNA level, it is reasonable to postulate that p53 gene expression in these two 
HMCLs are mediated at the transcriptional or post transcriptional level, rather 
than at the protein level.  
At the transcriptional level, aberrant gene promoter methylation is one of 
the ways by which gene expression can be silenced. To assess the possible role of 
this p53 silencing mechanism, the cells were treated with 5-Azacytidine (5-Aza), 
a potent global DNA demethylator, and p53 expression was then evaluated.  
As shown in Fig. 4.11A, 2.5 uM of 5-Aza treatment for 24h resulted in a 
marked increase in p53 transcript in both cell lines, together with a significant 
decrease in the cell viability (Fig. 4.11B). At the protein level, 5-Aza was also 
able to induce an elevation of p53 expression in KMS18 (Fig 4.11C). However, 
this was not seen at the protein level for JJN3 (data not shown), suggesting that 
other factors may further regulate protein expression of p53. 
To further confirm the direct effects of 5-Aza on the demethylation of p53 
promoter, methylation specific PCR (MSP) was performed by using PCR primers 
specific for methylated and unmethylated sequences on p53 promoter. MSP 
analysis showed a notable decrease of the methylated DNA and a distinct increase 
in the unmethylated DNA in both KMS18 and JJN3 (Fig. 4.11D). These data 
collectively suggests that the remaining allele of WT p53 in KMS18 and JJN3 
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was epigenetically suppressed by promoter hypermethylation. When we 
performed similar analyses on XG6, we also observed a demethylation process of 
its p53 when the cells were subjected to 5-Aza treatment, though no distict 
methylated p53 was observed at its basal level (Appendix Fig. S3).  Additionally, 
p53 mRNA expression was rescued, with a concurrent inhibition in cell survival 
with 5-Aza treatment (Appendix Fig. S3).  
In addition, we analyzed a publicly available methylation array dataset 
(GSE21304) [155] to assess the frequency of methylation of p53 promoter in MM 
patients. Of 161 patients in the dataset, only 5 (3%) had at least one probe in the 
p53 promoter region methylated (Fig. 4.11F). This suggests that methylation of 













Figure 4.11.  Promoter DNA hypermethylation is one of the possible p53 
silencing mechanisms in MM (A) JJN3 and KMS18 were treated with 2.5uM 5-
Azacytidine for 24h and the cells were harvested for RNA extraction and was 
followed by qPCR analysis with two p53 primers (1 and 2) spanning different p53 
regions. (B) Cell viability of KMS18 and JJN3 after 2.5uM of 5-Aza treatment for 
48h (C) KMS18 was treated with 5-Aza for 48 hours and the cells were harvested 
for nuclear/ cytoplasmic extraction and were subjected to Western blot analysis. 
(D) MSP-PCR was performed after the cells were treated by 5-Aza for 24h. 
Methylated and unmethylated p53 promoter specific primers were used for PCR 
amplification. (E) Probe positions of publicly available methylation array dataset 
(GSE21304) around 17p13. Individual exons of genes on forward and backward 
strands are depicted with lighter and darker gray bars while genes on forward and 
backward strands are indicated with symbols (+) and (-) as well as exon-enclosing 
red and blue dotted boxes, respectively. (F) Profiles of methylation level (beta) 
for probes indicated in (E). For each probe, samples with beta above threshold 









4.2.4 miRNA regulation of p53 
In view of the importance of miRNAs in regulating gene expression and 
the novel discovery of important p53-regulating miRNAs [56, 82], this mode of 
p53 suppression in our WT/- HMCLs were also investigated. Importantly in MM, 
it was found that both miR-25 and miR-30d were direct negative regulators of p53 
[57]. Based on this recent finding, miR-25 and miR-30d were then studied. 
Endogenous levels of miR-25 and miR-30d were checked to determine if 
there was over-expression of these miRNAs that could possibly inhibit p53 
translation. Interestingly, we observed a significantly higher expression of both 
miR-25 and miR-30d in the WT/- cells as compared to both WT/WT (H929 and 
MM.1s), indicating that these onco-miRs may actually be important p53 
regulators in the WT/- cells (Fig. 4.12A). This also reflected a situation whereby 
the p53 in the WT/- cells had a potentially higher predisposition to negative 
regulating onco-miRs as compared to myeloma cells with two intact copies of p53.   
Next, in order to ascertain if inhibition of these highly expressed miRNAs 
could rescue the expression level of p53; KMS18 and JJN3 were transfected with 
miRNA antagonist specific for miR-25 and miR-30d. Fig. 4.12B shows the 
inhibition level of miR-25 and -30d after treatment with its respective anti-
miRNAs. Taqman-PCR analysis, as shown in Fig. 4.12C, revealed that depletion 
of miR-25 by 60% (KMS18) and 80% (JJN3) was able to rescue ~70% and ~60% 
of p53 mRNA expression in KMS18 and JJN3, respectively. On the other hand, 
treatment with anti-miR30d that almost completely diminish miR-30d expression 
in both cell lines, rendered a non significant 30% and a striking 80% increase in 
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p53 transcript level in KMS18 and JJN3, respectively. These observations 
indicate that onco-miRs may in part play a role in silencing p53 expression in 












Figure 4.12. miRNA-mediated regulation of p53 expression in KMS18 and 
JJN3. (A) Endogenous levels of miR-25 and -30d of WT/WT (H929 and MM.1s) 
and WT/- (KMS18 and JJN3) HMCLs. (B) Taqman-qPCR analysis showing 
inhibition level of miR-25 and -30d after treatment with  50 nM specific anti-
miRNAs for 24 hours. (C) Real-time PCR analysis of p53 mRNA level in KMS18 





4.2.5 MM p53-target-gene-signature is associated with TP53 status and survival 
Collectively, our results suggest that abrogation or disruption in the p53 
pathway is of functional relevance in MM. As multiple abnormalities may perturb 
the p53 network, and the defective p53 manifest its effect through an attenuated 
p53 transcriptional function, we postulated that an analysis of p53 transcriptional 
targets that are not themselves affected by gene mutations or epigenetic 
alterations in myeloma would allow the identification process for a signature of 
abnormal p53 pathway. Since there is no effective method of identifying p53 
dysfunction in the clinic other than performing DNA sequencing to detect p53 
mutation and FISH for detection of p53 deletion, we undertake this approach in 
the hope of developing a more accurate prognostic marker that can define p53 
pathway deficiency.  
Based on the list of validated p53 targets [28] and by utilizing the MM 
datasets, HOVON and UAMS, a signature of p53 targets, that we called MM-p53-
target-gene signature, consisting of PUMA (apoptosis), GADD45 (cell cycle) and 
THBS1 (angiogenesis) was developed. These three genes were chosen as they are 
validated p53 target genes that had consistent correlation with each other across 
the datasets.  
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Analyzing the prognostic relevance of this MM-p53-target-gene signature, 
it was found that HMCLs with p53 abnormalities (WT/-, mutant and -/-) have 
significantly reduced signature indices as compared to WT/WT cell lines (p<0.05) 
(Fig. 4.13A), indicating that anomalies in TP53 gene function or expression 
would affect its transcriptional functions, hence, the lower expression of the p53 
target genes. Consistently, in MMRC patient dataset, p53 copy number status was 
also strongly correlated with our signature values (Fig. 4.13B). This suggests that 
our signature could be useful in capturing different defects in the p53 pathways. 
Considering the association between p53 dysfunction with genomic 
instability and patients’ survival [48, 153, 154], we wanted to know how the 
expression of this p53 pathway signature could act as a surrogate for these 
phenotypes. The HOVON and UAMS datasets  saw negative correlations between 
the p53 signature and chromosomal instability, indicating that lower p53 signature 
(defective p53 pathway) is associated with greater chromosomal instability 
[HOVON (r = -0.329, p = 1.502E-8), UAMS (r = -0.272, p = 6.125E-11)] (Fig. 
4.9C). Consistently, these results were further validated in APEX dataset (r= -
0.369, p = 1.832E-7)) (Fig. 4.13C). This is consistent with the expected effect on 
chromosomal stability when p53 is defective, validating our p53 signature. In 
addition, patients with high and low expression of the MM p53 target gene 
signature had significantly different survival in the HOVON (p=0.00175), APEX 
(p=0.00628) and UAMS (p=0.0203) datasets (Fig. 4.13D). Taken together, these 
results provide strong evidence for the important correlation of defective p53 
functions with its signature indices and subsequent poor survival in the patients. 
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Figure 4.13. p53 pathway signature and MM characteristics. (A) Comparison 
of p53 pathway signature index distribution in MM cell lines according to TP53 
locus status; intact locus (WT/WT), hemizygous deletion (WT/-) and homozygous 
deletion, mutation, no expression (-/-;Mut;No). (B) TP53 copy loss was 
associated with low signature index in MMRC patient dataset. (C) Correlation 
between p53 pathway signature index and chromosomal instability index in MM. 
(D) Comparison of MM patient prognosis based on p53 signature index. HOVON 




4.3 PRIMA-1 and its p53-independent mechanism 
The current data thus far indicated heavy dependence of MM cells on loss 
of functional p53 to thrive and survive. Critically, mutation of TP53 is a 
predominant feature in the late stages of MM such as PCL, and has been 
associated with disease progression and poor prognosis in the patients [66]. Given 
that the inactivation of p53 through any means at all, almost certainly conferred a 
deficiency of its downstream response, reactivation of p53 would serve as the 
most promising way of improving the patients’ outcome. In line with this study 
objective, PRIMA-1, a novel mutant-p53-reactivating agent was also analyzed. As 
it has shown potent anti-tumorigenic property in a mutant-p53-dependent as well 
as -independent manner, we reckoned that it would be interesting to explore if this 
compound could rescue the functional activity of p53 in myeloma cells.   
 
4.3.1 PRIMA-1 treatment did not induce the reactivation of p53 pathway in 
p53-mutant-HMCLs 
 Considering that the main role of PRIMA-1 is to reconstitute the 
transcriptional activities of mutant p53 by reversing its misfolded protein structure 
back to its wild type conformation, we have selected three p53 mutant HMCLs 
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and one p53 mutant lung cancer cell line to be treated with this drug to examine 
this effect. The potential reversal of mutant p53 protein into a functional 
transcription factor was then evaluated by checking for the expression of 
downstream targets via Western blot analysis.  
In tandem with what has been reported in the solid tumors, PRIMA-1 
treatment saw a complete restoration of the integrity of p53 pathway in NCI-H596, 
a non-small cell lung carcinoma cell line. The drug treatment rendered an 
apparent increased in the protein level of p21 and MDM2 and an evident 
upregulation of PUMA and NOXA, with no significant modulation of the p53 
level (Fig. 4.14A). This observation in a solid tumor cell line supports the 
previously published reports on mutant p53-dependent mechanism of PRIMA-1.  
Interestingly, in contrary to what has been reported in the solid tumors, 
treatment of HMCLs harbouring p53 mutants, RPMI-8226, U266 and KMS28BM, 
with an increasing concentration of PRIMA-1, up to 100 uM, did not yield any 
reactivation of p53 pathway, as evidenced by the absence of expression of p21, 
MDM2 and PUMA (Fig. 4.14B), indicating that there was no reconstitution of the 
p53 transcriptional function. There was also no change in the p53 expression level 
itself.  
Similarly, there was no effects seen on p53 pathway upon PRIMA-1 
treatment in the non-p53 mutant cells, KMS18 (WT/-), JJN3 (WT/-) and NCI-
H929 (WT/WT) as well as in the p53 null KMS11 (-/-). In the Western blot 
analysis, zero expression of p53 remains in the WT/- and -/-, whereas in the 
WT/WT, there was no obvious modification of the p53 protein level after the drug 
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treatment. The transcriptional function of these non-p53 mutants was also not 
affected by this drug as no alteration in the expression levels of its targets, p21, 





Figure 4.14. No reactivation of p53 pathway upon PRIMA-1 treatment in 
p53-mutant-HMCLs. (A) Non-small cell lung carcinoma cell line, NCI-H596 
showed reactivation of p53 pathway after 24 hours of treatment with increasing 
concentration of PRIMA-1. (B) No reconstitution of p53 transcriptional activity in 
the p53 mutant HMCLs after 24 hours of treatment with high concentration of 







4.3.2 PRIMA-1 induces cell toxicity in a mutant-p53-independent manner 
Since there was no change in the p53 activity and its pathway in the 
HMCLs treated with PRIMA-1, MTS assay was then performed to determine if 
these cells were sensitive towards this drug despite the absence of p53 pathway 
re-activation. Simultaneously, the efficacy of the drug was also tested on the p53 
non-mutant and -/- HMCLs. Interestingly, despite the unchanged p53 pathway 
activity, PRIMA-1 was able to decrease cell viability of all the cell lines tested, 
irrespective of their p53 status, in a dosage dependent manner (Fig. 4.15A).  
Parodoxically, p53 mutant cell lines, RPMI-8226 and U266 were not the 
most sensitive cells to this specific p53-mutant reactivating drug as compared to 
the other HMCLs. In fact, their cell viability was suppressed only from doses of 
50 uM and above, whereas other non-mutant cell lines seem to have gradual 
reduction of cell viability from as low as 25 uM onwards. This phenomenon 
reflects a p53-mutant-independent mechanism of the drug as it was found to be 
more efficacious in reducing the viability of the non-mutant HMCLs. Table 4.1 is 
the list of the IC50 of all the HMCLs tested.  
Of importance, the two most sensitive cell lines found were JJN3 and 
KMS11, and incidentally they both have a total absence of p53 mRNA and 
protein. The fact that these p53 deficient cells are the two most sensitive cell lines 
suggests that the drug also work through a p53-independent mechanism. 
Recapitulating similar trend, annexin-V apoptosis assay also showed that PRIMA-
1 treatment yields the highest percentage of cell death in p53-deficient cells, JJN3 
and KMS11 (Fig. 4.15B). Treatment with as high as 50 uM of PRIMA-1 only 
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managed to kill up to 50% of the cells in the remaining cell lines, including those 




Figure 4.15. PRIMA-1-mediated toxicity follows a p53-independent 
mechanism. (A) PRIMA-1 treatment for 48 hours decreased cell viability of all 
the HMCLs irrespective of their p53 status.JJN3 and KMS11 were the two most 
sensitive HMCLs. (B) 50 uM of PRIMA-1 treatment for 48 hours induced highest 
amount of cell death in HMCLs with no expression of p53 mRNA and protein 







HMCL p53 status IC50 (uM) 
NCI-H929 WT/WT 54.8458 
KMS28BM Mutant 65.3732 
RPMI-8226 Mutant 71.6141 
U266 Mutant 70.3264 
XG6 WT/- 83.1861 
KMS18 WT/- 88.8962 
JJN3 WT/- 32.2331 
KMS11 -/- 16.3025 
 
 
Table 4.1. IC50 of each HMCLs upon treatment with PRIMA-1 in MTS assay. 
 
 
4.3.3 p53 knock-down cells are more sensitive to PRIMA-1 
In order to further validate the sensitivity of the drug in p53-deficient-
background and to exclude differential genetic background in the cell lines 
confounding the real effects, the isogenic p53 knockdown cells NCI-H929 (shCtrl 
and sh-p53-#21) that was established earlier (in Fig. 4.7A) was treated with 
PRIMA-1 at the indicated concentrations for 48 hours for cell viability assay and 
24 hours for annexin-V apoptosis assay. p53 silencing rendered the cells to have 
significantly increased sensitivity towards the drug.  This was reflected by the 
dramatic reduction in cellular proliferation (Fig. 4.16A) and remarkable 
enhancement in the number of annexin-v-positive cells in the NCI-H929-shp53 as 
compared to its isogenic control (Fig. 4.16B). At 25 uM, the p53-deficient-NCI-
H929 was almost entirely wiped out, whereas the shCtrl cells were seen to follow 
a gradual route of reduction in cellular viability. Thus, this finding further 
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strengthens the hypothesis that PRIMA-1 indeed has a heightened toxicity in a 






Figure 4.16. p53 knockdown cells are more sensitive to PRIMA-1. (A) MTS 
viability assay of NCI-H929 isogenic cell lines after treatment with 48 hours of 
PRIMA-1. A sharp plunge in the cell viability in the NCI-H929-shp53 cells as 
compared to its isogenic control was observed. (B) Annexin-v apoptosis assay on 
DMSO- and PRIMA-1- treated- H292 isogenic cells. PRIMA-1 killed almost all 
of NCI-H929-shp53 cells at 25 uM, whereas its isogenic control was shown to 












4.3.4 PRIMA-1 treatment induces caspase-dependent apoptosis 
PRIMA-1 treatment has been shown to induce caspase activity which 
eventually causes cell death in various solid tumors [100, 112]. In order to 
determine if PRIMA-1 follows the same route in MM, PRIMA-1-treated cells 
were probed for the protein expression of caspases-3, -8 and -9 (Fig. 4.17).  
Both JJN3 and KMS11 showed a reduction of pro-caspase 3 and an 
increase of its cleaved derivative, which is followed by a significant upregulation 
of PARP cleavage (Fig. 4.17A), reflecting caspase-dependent cell death. 
Interestingly, when probed for caspases-8 and -9, cleavage of both of these 
apoptosis mediators was evident upon PRIMA-1 treatment, indicating the 
involvement of both the extrinsic and intrinsic apoptosis pathway, respectively 
(Fig. 4.17A).  
In support of this finding, the NCI-H929 p53 knockdown isogenic cell line 
also demonstrated the same trend of caspases expression, whereby caspases-8 and 
-9 were also found to be cleaved concurrently, which was then followed by the 
cleavage of caspase-3, leading to the significant induction of PARP cleavage (Fig. 
4.17B). This is again observed only in the NCI-H929-shp53 cells and not in the 
NCI-H929-shCtrl cells, thus, further confirming the previous results that PRIMA-










Figure 4.17. PRIMA-1 treatment induces caspase-dependent apoptosis. (A) 
PRIMA-1 causes cleavage of caspases -8, -9 and -3 in JJN3 and KMS11 after 24 
hours treatment with 25uM PRIMA-1. (B) The same trend was seen in NCI-H929 




4.3.5 Gene expression profiling of PRIMA-1-treated samples 
 To further elucidate the p53-independent cytotoxic effect of PRIMA-1 in 
MM, gene expression profiling (GEP) was performed to extract potential genes 
and the possible pathways that may be involved in the killing mechanism of the 
drug. The two most sensitive cell lines (JJN3 and KMS11) were subjected to GEP 
analysis by using Affymetrix Microarray platform. There were clear and distinct 
groups of differentially expressed genes between the untreated and PRIMA-1-
treated JJN3 and KMS11 (Fig. 4.18A). Among these differentially expressed 
genes, 22 common genes were identified to be upregulated or downregulated in 
both PRIMA-1-treated-JJN3 and –KMS11 (fold change= 2, p< 0.05). From this 




because they have been reported to be associated with cancer: Phorbol-12-
myristate-13-acetate-induced protein 1 (PMAIP1 or NOXA), Protein phosphatase 
1 regulatory subunit 15A (PPP1R15A or GADD34) and heat shock protein 70 
(HSP70) family members (HSPA1A, HSPA1B and HSPA6). The same samples 
used for the microarray profiling were then subjected to real-time PCR analysis 
for the validation of the GEP results. Indeed, a significant increase in the mRNA 
levels of NOXA, GADD34 and HSP70, by at least two folds was observed in the 
PRIMA-1-treated samples compared to the untreated ones (Fig. 4.18B).  
Next, in order to dissect the pathway that PRIMA-1 is most likely to target, 
the gene ontology (GO) was investigated by using the online DAVID software. 
The analysis produced two mutual pathways that are significantly enriched upon 
the drug treatment, namely, the response to topologically incorrect protein 
(misfolded protein) and the response to unfolded proteins (Table 4.2). Both of 
these responses are mainly regulated in the endoplasmic reticulum, whereby stress 
arising from the accumulation of unfolded and misfolded proteins would result in 
the activation of the endoplasmic reticulum stress pathway as a means of restoring 
normal protein homeostasis. Referring back to the GEP and real time-PCR results, 
the upregulated HSP70 and GADD34 are both bona fide ER stress markers. 
NOXA has also been reported to be actively involved in ER-stress-mediated 
apoptosis [130, 131]. Thus, in view of this, we hypothesized that PRIMA-1 
toxicity in MM is mediated via the ER stress pathway (also known as unfolded 









Figure 4.18. Gene expression profiling of PRIMA-1-treated samples. (A) Heat 
map demonstrating the differentially expressed genes in the DMSO and 25 uM- 
PRIMA-1-treated samples in JJN3 and KMS11. (fold change= 2, p< 0.05) Red: 
upregulation, Blue: downregulation (B) Real-time PCR validation of GEP 
analysis of DMSO and 25 uM PRIMA-1 treated samples revealed consistent 







Table 4.2. Gene ontology pathway analysis of PRIMA-1-treated-JJN3 and -
KMS11. This analysis unveiled the enrichment of unfolded and misfolded protein 





4.3.6 Induction of ER stress pathway in response to PRIMA-1 treatment 
We next validated if PRIMA-1 treatment could indeed trigger ER stress 
and induce the unfolded protein response pathway. PRIMA-1-treated JJN3 cells 
were probed for various established ER stress markers by Western blot (Fig. 
4.19A). The most upstream component of ER stress pathway is the molecular 
chaperone HSP70 family member, GRP78. Upon PRIMA-1 treatment, this 
protein was significantly induced in a time dependent manner. As GRP78 is 
required to bind to accumulated unfolded and misfolded proteins in the ER, its 




Subsequently, PERK was then phosphorylated in response to the drug 
treatment, with peak phosphorylation occurring at 12th hour treatment. Following 
that, its substrate, eIF2a was also phosphorylated, with a parallel tapering of the 
total eIF2a level. Consequently, there was a time dependent upregulation of the 
downstream proteins such as CHOP and GADD34, both of which are hallmarks 
of ER stress-induced toxicity.  
Expression of anti-apoptotic proteins, BCL-2 and MCL-1, which are 
CHOP transcriptional targets, are attenuated, suggesting that the significant 
increase in the CHOP expression was leading to suppression of these important 
anti-apoptotic genes to provide a conducive environment for cellular apoptosis. In 
conjunction, NOXA was also upregulated at the protein level in a time dependent 
manner (Fig. 4.19A). The induction of pro-apoptotic proteins and suppression of 
anti-apoptotic proteins subsequently induced a cascade of caspase-dependent cell 
death, involving the intrinsic (caspase-9) and extrinsic (caspase-8) pathway (Fig. 
4.19B).  
Due to the fact that p53 expression is absent in JJN3, we hypothesized that 
its subfamily member, p73, may be acting as a surrogate tumor suppressor protein. 
Indeed, p73 protein level was significantly upregulated in response to PRIMA-1 
treatment, with the expression level peaking at the 24th hour (Fig. 4.19C). 
Real-time qPCR analysis was then performed to validate the expression 
level of these ER stress markers at the mRNA transcript level. All the ER markers 
tested, namely the GRP78, ATF4, CHOP and GADD34, were consistently 
increased at the mRNA level with PRIMA-1 treatment (Fig. 4.19D). Importantly, 
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NOXA and p73 mRNA were also upregulated, reflecting the same trend observed 
by Western blot analysis. 
With the robust induction of these ER stress markers, our data suggest that 
the ER stress pathway or UPR is one of the pathways targeted by PRIMA-1. 
Specifically, PRIMA-1-induced-ER stress is mediated mainly through PERK 
network as evidenced by the increased expression of its downstream elements, 
namely p-PERK, p-eIF2a, ATF4, CHOP and GADD34. Further substantiating 
this notion, knockdown of CHOP (Fig. 4.19E and F), which is a direct target of 
transcription factor ATF4 and also the main mediator of apoptosis in ER stress 
response, rendered a reduced sensitivity of the cells to PRIMA-1 (Fig. 4.19G). 
It is also important to note that since p73 was also significantly increased 
in response to the drug, the involvement of this tumor suppressor in PRIMA-1-
mediated-toxicity also cannot be ruled out.  
 





                   
 
                 











Figure 4.19. PRIMA-1 treatment induced various ER stress markers in MM 
cells. (A) Western blot analysis probing for various ER stress markers in JJN3 
cells treated with 25 uM PRIMA-1 at different time points. (B) The expression 
level of proteins involved in the apoptotic responses, upon 25 uM PRIMA-1 
treatment at different time points. (C) p73 protein expression of 25 uM PRIMA-1 
treated JJN3 cells at different time points. (D) Real time PCR analysis of ER 
stress markers validated the findings in Western blot analysis. (E&F) JJN3 was 
transfected with 100nM siCtrl and siCHOP for 24 hours and mRNA (E) and 
protein (F) were isolated to check for knockdown efficiency. (G) Percentage 
specific apoptosis upon 25 uM PRIMA-1 treatment for 24 hours after CHOP 




4.3.7 ER stress induced by PRIMA-1 did not follow the IRE1 and ATF6 arms 
 Next, we then went on to interrogate the other two arms of the pathway, 
namely the IRE1 and ATF6 arms, to determine their activity and response status 
to PRIMA-1 treatment. Splicing of XBP1 mRNA is the hallmark for IRE1 
activation and it has been reported that the splicing is an early event upon the 
pathway activation [156]. In view of this, the cells were treated with PRIMA-1 at 
earlier time points and were then harvested for mRNA isolation and were 
subjected to reverse-transcription PCR.  
As shown in Fig. 4.20A, the drug did not actually yield any splicing of 




tunicamycin, which is a potent ER stress inducer, for 6 hours, caused an obvious 
expression of XBP1 spliced variant (Fig. 4.20A). Therefore, this indicates that ER 
stress pathway activation in response to PRIMA-1 was not cruising through the 
IRE1-XBP1 route. As this route is essential for the differentiation of B-cells to 
plasma cells, it has been associated with pro-survival response in myeloma. Thus, 
we postulated that PRIMA-1 could play its anti-myeloma role by suppressing the 
pro-survival effects of IRE1-XBP1. Indeed, PRIMA-1 was found to be able to 
rescue the XBP1 splicing induced by tunicamycin when both compounds were 
co-incubated in JJN3 (Fig. 4.20B). 
 On the other hand, to examine if the ATF6 arm was affected by the 
exposure with PRIMA-1, a luciferase reporter assay was performed, utilizing a 
firefly luciferase reporter plasmid with an ER stress responsive element (ERSE) 
where ATF6 binds (Fig. 3.1). As shown in Fig. 4.20C, PRIMA-1 treatment was 
seen to increase the luciferase activity of only two folds, whereas the cells treated 
with the positive control treatment, tunicamycin, displayed a sharp rise in the 
luciferase activity of more than five folds (p=0.026), as compared to the DMSO 
control cells. Even though combination treatment of both PRIMA-1 and 
tunicamycin was seen to enhance the luciferase expression deriving from each 
single agent treatment, the effect of PRIMA-1 in increasing the luciferase activity 
induced by tunicamycin was not significant (p=0.340). This finding indicates that 
PRIMA-1 treatment did not have significant effects on the ATF6 arm of ER stress 
pathway. Furthermore, Western blot analysis (Fig. 4.20D) showed gradual 
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reduction of ATF6 expression upon PRIMA-1 treatment, thereby ruling out the 







Figure 4.20. PRIMA-1 has little effects on the IRE1 and ATF6 arms of the 
ER stress pathway. (A) JJN3 cells were treated with 25 uM PRIMA-1 at the 
indicated time points and RT-PCR was performed with specific XBP1 primers. 10 
ug/ml tunicamycin treatment for 6 hours was used as positive control. (B) JJN3 
was treated with a combination of 25 uM PRIMA-1 and 10 ug/ml tunicamycin for 
8 hours and RT-PCR was performed. TM: Tunicamycin. (C) Luciferase activity 
displayed by JJN3 when treated with 25 uM PRIMA-1, 10ug/ml tunicamycin and 
combination of both for 8 hours (* p<0.05) N.S: Non-significant. (D) ATF6 








4.3.8 PRIMA-1 induces reactive oxygen species (ROS) production  
! ROS is often associated with the induction of ER stress pathway and 
cancer [157-159], whereby, scavenging ROS has been shown to decrease 
unfolded protein load and reduce the ER stress-induced-apoptosis response [158, 
160]. Delving deeper into PRIMA-1’s mechanism of action, we decipher if ER 
stress induction by PRIMA-1 was mediated by ROS production. In this instance, 
JJN3 cells were exposed to 25 uM PRIMA-1 for different time points and 
intracellular ROS generation was evaluated by CM-H2DCFDA fluorescence 
staining. 
 As shown in Fig. 4.21A, there were no significant changes in the FITC 
profile at earlier time points, up to 12th hour of treatment. The surge of the number 
of CM-H2DCFDA-stained-cells was clearly observed only at the 16th hour, and 
its elevation was sustained up to 30th hour, indicating an increase of ROS 
generation. In contrast to what we have expected, this finding strongly hints that 
ROS involvement in PRIMA-1 treatment was a late event. We therefore 
hypothesize that ROS may be acting as a downstream factor of UPR or the ER 
stress pathway response. This is consistent with the fact that at the 6 hours time 
point, the ER stress markers were already starting to show a surge in their 
expression level, and finally displaying an intense expression at 24 hours (Fig. 
4.19A), whereas ROS induction was only showing at 16th hour onwards. These 
observations depicted a phenomenon whereby PRIMA-1-mediated-ER stress 
response may have disrupted the oxidative conditions in the cells, thus, increasing 
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the production of free radicals mediating intracellular ROS homeostasis, which 
ultimately causes cell death. 
If this is true, obliteration of the ROS production would rescue the 
PRIMA-1-induced cell death. Indeed, quenching of intracellular ROS by N-
acetyl-L-cystein (NAC), which is a robust ROS scavenger, led to a significant 
inhibition of PRIMA-1 mediated apoptosis (Fig. 4.21B). Concurrent exposure to 
PRIMA-1 and NAC saw a great recovery of the cells from apoptosis, in which its 
rate was almost back to its basal level as in the DMSO control cells, thus, strongly 
indicating an ER stress-ROS-dependent apoptosis response. Fig. 4.21C showed 
the quantification of the positively-stained cells. 
 Furthermore, scavenging ROS by NAC was seen to rescue the PRIMA-1-
induced expression of GADD34 and CHOP, both of which are late and 
downstream proteins of PERK pathway (Fig. 4.21D). In contrast, there was no 
obvious change in the expression level of the earliest ER stress responsive protein, 
GRP78, indicating that late ER stress pathway factors and not the early factors 






























Figure 4.21. Generation of ROS in response to PRIMA-1 treatment. (A) 25 
uM of PRIMA-1 treatment at different time points yields significant surge of ROS 
production in JJN3 at later time points as indicated by FITC-positivity. (B) 24 
hours treatment of JJN3 with PRIMA-1 and ROS scavenger, NAC, 5 mM, 
inhibited PRIMA-1-induced apoptosis. (C) Quantitation of annexin-V positive 
cells from FACs analysis. (D) JJN3 was co-treated with PRIMA-1 (25 uM) and 
NAC (5 mM) for 24 hours and rescue of PRIMA-1-induced- late ER stress 




4.3.9 Drug combination response of PRIMA-1 and bortezomib in MM 
 The current data collectively supports the efficacy of PRIMA-1 as a 
potential therapeutic agent for MM by inducing a toxic ER stress response. 
Notably, the dosage required for the cells to be sensitive to this drug was detected 
to be in the micromolar ranges as demonstrated in the cell viability assay (Table 
4.1). In view of this, we figured that it would be ideal and pivotal if the effective 
concentration of PRIMA-1 could be tapered by a combination treatment with an 
established anti-myeloma agent.  
In this instance, bortezomib, which is a proteosome inhibitor that has 
garnered a good track record in improving the outcome of MM patients, were 




compound is especially relevant since it has been reported that cells with 
increased unfolded protein contents are more sensitive to bortezomib [132, 161].  
In relation to this, we postulated that both of these ER stress- inducing agents 
would behave synergistically in the presence of each other.  
JJN3 were subjected to treatment combination of lower PRIMA-1 
concentration (10 uM) with an increasing low doses of bortezomib. MTS assay 
demonstrated that 10 uM of PRIMA-1 treatment was only able to suppress ~20% 
of the viability of JJN3, whereas bortezomib with its low effective concentration 
of 5 nM was sufficient to render more than 30% reduction in cell viability. 
Importantly, a significant decrease in cell viability was observed in response to 
treatment with combined PRIMA-1 and bortezomib compared with either of the 
single agent alone (Fig. 4.22A). In silico analysis for synergism noted an additive 
and synergistic response at different concentrations of bortezomib, which is 
demonstrated by a combination index (CI) of 1 or less than 1, respectively.  
 Even though bortezomib have generally provided promising outlook on 
the patients’ prognosis, resistance towards this drug in the clinic remains 
inevitable. To illustrate the translational relevance of PRIMA-1 in the 
bortezomib-resistant cases, the efficacy of PRIMA-1 was also experimentally 
tested in vitro on a bortezomib-resistant HMCL, RPMI-8226-P100V. This cell 
line has been generated to be resistant to bortezomib up to 100nM concentration 
(Fig. 4.22B) whereas its parental cell line, RPMI-8226 has an IC50 of ~4 nM 
towards bortezomib (data not shown). Like other HMCLs, PRIMA-1 treatment of 
RPMI-8226-P100V resulted in a dose dependent decrease in cellular viability (Fig. 
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4.22C), indicating that it may have a potential role in targeting the bortezomib-
resistant cases.  
Importantly, when PRIMA-1 was combined with bortezomib in treating 
RPMI-8226-P100V, we observed a restoration of sensitivity of these cells towards 
bortezomib (Fig. 4.22D). At single agent of 25 nM and 50 nM of bortezomib, the 
cells were still fully viable. However, when both agents were co-incubated, a 
significant 60% and 80% decrease of cell viability were noted for 25 nM and 50 
nM bortezomib, respectively. CI values obtained for these combinations were 
approximately 1.0, suggesting an additive effect of both drugs.  
 






















Figure 4.22. Drug combination effects of PRIMA-1 and bortezomib on 
HMCLs. CI=1 indicates additive effect, CI<1 indicates synergistic effect. (A) Co-
incubation of PRIMA-1 and bortezomib in JJN3 at the indicated concentrations 
for 48 hours and cell viability was measured by MTS assay.(B) Cell viability of 
RPMI-8226-P100V in response to high concentration of bortezomib treatment 
(IC50: 120nM). (C) Efficacy of PRIMA-1 on RPMI-8226-P100V. Gradual 
reduction of cell viability observed in response to increasing concentration of 
PRIMA-1 for 48 hours. (D) Additive effects demonstrated by P100V treated with 







CHAPTER 5: DISCUSSION 
 
5.1 Haploinsufficiency of p53 in multiple myeloma 
The clinical relevance of 17p13 deletion in myeloma is already well 
established. MM patients with 17p13(del) have unfavourable outcome even with 
current improved therapeutics. Critically, the prevalence of 17p13 (del) increases 
in more advanced stages such as plasma cell leukemia and extramedullary disease 
[67, 73]. TP53, which encodes the p53 tumor suppressor, is situated within this 
deleted locus. While it is logical to implicate p53 as the critical tumor suppressor 
gene deleted in this region, there is surprisingly little published data in myeloma 
that directly supports this notion. Our analysis on the MMRC dataset identified 
that majority of the 17p13(del) cases had loss of large segment of or the entire p-
arm of chromosome 17. Although little information about a critically deregulated 
gene can be derived from such large deletions, three further cases had 
substantially smaller interstitial deletions that were more informative for gene 
mapping analysis. This minimally deleted region (0.67Mbp), contained 32 genes, 
and importantly includes TP53.  
This piece of data corroborated with the results published by Boyd et al. 
from the Medical Research Council (MRC) dataset analysis [19], whereby, TP53 
was also consistently found to be contained within the 17p13 minimally deleted 
region (0.55Mbp) in their patient cohort. When they extended their analysis to 
another established MM dataset from the Intergroupe Francophone du Myelome 
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(IFM), they also observed the similar scenario. Again, TP53 reside in the 
identified minimally deleted region of 17p13 (0.25Mbp).   
In the MRC dataset, only 2 genes within the minimally deleted area, 
namely TP53 as well as SAT2, have significantly lower expression in the 
17p13(del) cases versus non deletion cases [19]. The fact that TP53 was 
frequently lost in this high risk group of patients, as indicated in the analysis from 
three independent myeloma datasets (MMRC, MRC and IFM), lends some weight 
to the hypothesis that p53 is the critically deregulated gene in the 17p13 region. In 
addition, screening for p53 mutations have also revealed a higher mutation rate in 
cases with 17p13(del) as compared to those without [19, 65]. In cases without 
mutation, which is in the majority of 17p13(del), it is also possible that the 
remaining p53 has also been inactivated by various alternative means [19]; 
whereas in those with no inactivation of the remaining allele, one functional copy 
of TP53 may simply be not enough for its optimum efficiency. Indeed, absolute 
dysregulation of p53 has then been associated with poor prognosis and higher 
resistance to standard treatment in the patients [15, 66, 67, 70], indicating the 
clinical importance of this abnormality. These clinical correlations together with 
the fact that the prevalence of p53 abnormalities increases from the pre-malignant 
(MGUS) to the advanced stage of the disease (PCL) support TP53 as the likely 
critical gene in 17p13. 
It is crucial to note that homozygous deletion of p53 is extremely rare, 
with monoallelic deletion being predominantly found [19, 67, 73]. In addition, in 
majority of cases with 17p13 deletion, there is no clear evidence of inactivation of 
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the remaining allele. In view of this, we hypothesized that if p53 is indeed the 
critical tumor suppressor on 17p13, it must actually act as a haploinsufficient TSG 
in promoting myelogenesis. Haploinsufficiency is a condition whereby one copy 
of the gene is insufficient for its proper function, hence, increasing tumor 
formation tendency [162]. 
We therefore assessed p53 function in a panel of HMCLs to see if p53 
function could be affected by the presence of monoallelic deletion. Indeed, we 
demonstrated that one copy loss was already enough to attenuate p53 expression 
and function. This data is in agreement with a clinical study from UAMS that 
demonstrated a significant correlation between p53 mRNA expression with p53 
deletion [70, 78]. In relation to the p53 baseline expression, we saw that the tumor 
suppressor activity was already compromised (either partially or completely) in 
the p53WT/- cells. Even though XG6 was still responsive to the drugs, the 
response was almost 50% lower than WT/WT cells and the other two WT/- 
(KMS18 and JJN3) showed absolute defective p53 response again correlated with 
the negligible p53 protein expression in these cell lines. These observations 
clearly suggest the significance of p53 deletion in disrupting the functional 
activity of p53 in response to the genotoxic and non-genotoxic stress, whereby its 
functionality is strongly correlated with the gene and protein dosage. 
In both KMS18 and JJN3, the absence of basal p53 protein expression 
resulted in a complete abrogation of the p53 response pathways as evidenced by 
the absence of the transcription of its downstream targets and a significantly 
higher resistance towards apoptosis induction in response to etoposide and nutlin-
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3. This is consistent with previous data in primary MM samples where those with 
wild type p53 but did not show a nutlin-inducible p53 expression were completely 
resistant to nutlin-3 [4]. In addition, a previous study has also revealed that in 
HCT116 p53+/- with low p53 mRNA and protein expression, there was a 
defective induction of p21 and MDM2, indicating the need for a threshold amount 
of p53 for its functional transcriptional activity [148]. Providing further support 
for this is another study demonstrating that MDM2 promoter activation by p53 
was also far less efficient in p53+/- in vivo model [162, 163].  As mentioned 
earlier, the UAMS study by Xiong et al. has shown the correlation between p53 
deletion and low mRNA expression level, which in turn was significantly 
associated with poor survival outcome [70]. This is likely attributable to the 
absence of functional p53 activity [19, 70, 78]. Overall, our current data provide 
strong evidence that p53 is haploinsufficient in myeloma, and supports the notion 
that TP53 may be the critical gene deleted on chromosome 17p.  
The dosage dependence of p53 function and its haploinsufficiency were 
subsequently validated by performing p53 knockdown in NCI-H929 (WT/WT) 
and p53 re-expression in JJN3 (no mRNA and protein). Depletion of p53 
expression severely attenuated the p53 tumor suppressive functions, whereas 
rescue of p53 expression in turn completely restored its transcriptional activities. 
Essentially, these in vitro data were also coherent with the findings from in vivo 
studies, whereby p53+/- mice, with lower endogenous p53 dosage were more 
susceptible to succumb to an array of tumors as compared to its p53+/+ 
counterparts [162, 163]. Further evidence for p53 haploinsufficiency was also 
!121!
!
provided by another in vitro study utilizing p53 heterozygous thymocytes which 
revealed an intermediate partial resistance to apoptosis induced by ionizing 
radiation and etoposide [164]. To the best of our knowledge, our finding is the 
first evidence describing p53 haploinsufficiency in myeloma.  
 
5.2 Negative regulation of p53 
 The conventional understanding about a TSG as explained in the two-hit-
Knudson model is that loss of function of one copy of the gene would not be 
sufficient to cause tumor formation, presumably due to the compensatory actions 
of the intact copy. However, it has long been accepted that TP53 represents an 
exception to this theory. Although our evidence thus far suggests that p53 is a 
haploinsufficent TSG in myeloma, we also think that there may also be other 
mechanisms of p53 inactivation in the WT/- cases, so as to completely abolish the 
p53 tumor suppressive function. In this regard, our study has highlighted the 
complexity of p53 pathways in myeloma.  
Our studies revealed that MDM2 over-expression could potentially be an 
important factor contributing to the loss of function of p53 in MM. XG6 showed 
high MDM2 expression level, indicating that its compromised p53 regulatory 
pathway could have been further suppressed by the negative regulating effects 
imposed by the overproduction of MDM2. When the importance of MDM2 over-
expression was validated in the clinical samples, we found that high MDM2 
expression was associated with significantly poorer survival. Our clinical finding 
is in line with a previous study reporting on the presence of MDM2 gene 
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amplification in patient samples [73] and the incidence of high MDM2 expression 
in advanced stage of MM in PCL [79]. However, ours is the first to show an 
unfavorable outcome in newly diagnosed patients with high MDM2 expression. 
Furthermore, the fact that inhibiting MDM2 by nutlin-3 was efficacious in 
eradicating myeloma cells, such as in WT/WT (NCI-H929 and MM.1s) and some 
WT/- (XG6) HMCLs, as well as in MM primary samples [4, 95] indicated that 
MDM2 is indeed a critical element in p53 dysregulation in MM.  
 Even though we did not observe any overproduction of MDM4 in our 
WT/- cell lines, we do not rule out its possible role in suppressing the activities of 
wild type p53. This notion is established based on the fact that amplification of 
chromosome 1q has been consistently reported to be an important prognostic 
marker for MM [2, 81]. Given that MDM4 resides in this location of the genome, 
it is relevant that amplification of this region confer an overproduction of its 
protein which potentially also act on p53 to suppress its transcriptional and 
downstream activity.  
Further interrogation revealed that methylation of TP53 promoter was 
another important mechanism of inactivating p53. This was evidenced by a re-
expression of p53 in both KMS18 and JJN3 upon treatment with 5-Azacytidine, a 
potent global DNA demethylator, and a subsequent depression in cell viability.  
Methylation of TP53 has been less frequently reported [61, 89] as compared to 
other TSG such as p16, SOCS-1 and mir-34B [17, 121, 165, 166]. In the existing 
reports, p53 promoter was detected to be densely methylated in certain HMCLs 
and treatment with zebularine, another DNA methyltransferase inhibitor was able 
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to rescue the expression of p53, and subsequently induced apoptosis [61, 89]. 
However, the p53 allelic and mutational statuses of the cell lines were not taken 
into account in these analyses. Our current finding from the analysis of WT/- cells 
implicates that TP53 promoter hypermethylation could be an important 
mechanism for silencing of the remaining allele of p53 in the WT/- MM cases, 
thereby causing p53 LOH. Analysis of a large patient dataset in which 
methylation array was performed [155] revealed that methylation of the p53 
promoter was a relatively rare event (5%) in myeloma patients. This suggests that 
other mechanisms silencing the remaining gene allele may be involved.  
In this regard, aberrant expression and function of clinically important 
p53-regulating-miRNAs such as miR-25 and miR-30d that have been reported in 
myeloma [57, 83] was further interrogated. Inhibition of these miRNAs by its 
specific inhibitor was able to rescue p53 expression by 70% (anti-miR-25) and 80% 
(anti-miR-30d) in KMS18 and JJN3, respectively. This indicates that miR-25 and 
miR-30d in part contributed to the silencing of the remaining WT allele in 
KMS18 and JJN3. In addition, these miRNAs were also found to be 
pathologically important for p53 function in NCI-H929 [57]. The role of these 
miRNAs in affecting p53 functions in patient samples will need to be further 
verified.  
Summarizing this part of the project, even though it is commonly believed 
that p53 inactivation often occurs through post-translational modifications, i.e. via 
the actions of either MDM2 or MDM4, which is also the case found in our XG6 
(WT/-), the current results also demonstrated the importance of TP53 regulation at 
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the transcription level, whereby the aberrant methylation of its promoter silenced 
the activity of its remaining allele in the WT/- cases. In addition, over-expression 
of onco-miRs also plays a role in abrogating p53 functions. These findings 
highlight the diverse mechanisms by which TP53 may be inactivated in MM, 
indicating that re-activating p53 would be a crucial clinical approach. 
Furthermore, it also implies that abrogation of p53 function is indispensable for 
driving myelomagenesis.  
 
5.3 Clinical relevance of the in vitro findings 
 In the clinic, molecular assessment of p53 status in patients’ samples by 
using the standard sequencing technology, FISH and IHC are still considered 
incomplete assessors of p53 functional defects as there are many possible 
mechanisms that can result in deficit in p53 pathways. For example, copy number 
and mutation status of TP53 can be efficiently ascertained from FISH and 
sequencing, respectively, however, if the sample was detected to have a 17p13 
monoallelic deletion, the activity of its p53 downstream phenotype still remains 
questionable as proven by our in vitro functional analyses. Moreover, it has been 
reported that not all p53 mutations (at different spots in the gene) have equal 
effects. While it has been a universal understanding that mutations of the gene 
confer loss of functions, some may actually still retain partial activity [167, 168]. 
For these reasons, the current understanding has highlighted the absence of a 
single molecular assessment of p53 status that can provide a direct indication of 
p53 function. This event is especially true in MM.  
!125!
!
Therefore, it would be useful to develop a biomarker that can assess the 
integrity of the p53 pathway. It is noteworthy that all the different abnormalities 
described in Section 4.2 eventually leads to the perturbation in the p53 
downstream function. Since p53 protein executes its tumor suppressive properties 
by transactivating downstream genes, we figured that a good way to summarize 
its downstream functionality would be through the expression of its target genes.  
We found that HMCLs with p53 abnormalities (mutations, deletions and 
no expression) have significantly reduced expression of our derived myeloma-
p53-target-gene signature as compared to WT/WT cell lines. Importantly, we also 
found a strong association between the p53 target gene signatures and patients’ 
overall survival in three independent myeloma datasets (HOVON, UAMS and 
APEX), denoting the clinical importance of transcription-dependent activity of 
p53 in MM. These data indicate that the p53 target gene signature could be used 
to reflect the functionality of TP53 and can potentially be a surrogate marker for 
p53 inactivation and subsequent patient prognosis. This notion is supported by a 
previous study which has also highlighted the importance of p53 target genes in 
myeloma progression, by reporting close association between their p53 signature 
with p53 expression and poor clinical outcome [70]. Essentially, our signature 
was generated from a curated approach that eliminates confounding genes that are 
themselves deregulated genetically or epigenetically in myeloma, therefore, 
yielding only 3 genes in the final signature set. Performing analysis on small 
number of markers like this in the clinic would also seem more feasible and 
efficient. The current data suggests that p53 signatures could be used as an 
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alternative means to represent p53 dysfunctions should data on p53 abnormalities 
be not available, although this will need to be further validated clinically. The 
clinical utility of p53 gene signature for prognosis has already been described in 
other cancer models such as breast cancer [169], prostate cancer [170] and lung 
cancer [171], implying that similar principles can be extended to MM.  
Of importance, our study also provides some potential avenue for 
therapeutic intervention in MM with 17p13(del). Essentially, p53 function can 
still be active in some cases with p53 hemizygous deletion, i.e those with basal 
p53 protein expression (XG6), albeit at a compromised efficiency. This means 
that standard chemotherapy may not be enough to elicit efficient apoptosis in 
these cases. Our current evidence highlights the attractive strategy of 
incorporating the non-genotoxic nutlin-3 into the treatment regime as an adjuvant. 
Besides enhancing the killing capacity, it can also be used as a means to alleviate 
the collateral damage brought upon by chemotherapeutic drugs. This is proposed 
based on the knowledge that nutlin-3 induces growth arrest instead of causing 
cytotoxicity in normal cells that have WT p53 [4, 172]. Therefore, it is possible to 
minimize the chemotherapy-induced toxicity on normal cells by administering 
nutlin-3 first to momentarily halt the growth of normal cells and subsequently the 
genotoxic drugs to target only the proliferating cancer cells. Potential clinical 
application of nutlin-3 was further highlighted when it showed great synergism 
with various genotoxic drugs, including bortezomib, with little toxicity to normal 
bone marrow cells [95-97]. Based on these reports, we therefore propose that 
nutlin-3 is a promising therapeutic strategy for high-risk 17p13(del) patients. 
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Moreover, this timely finding on the importance of basal p53 expression 
implies that it can be used to gauge the responsiveness of the patients to 
treatments such as nutlin-3, thus, making it a potentially useful predictive marker. 
Our observation is novel as previous studies in MM did not specifically examine 
the impact of TP53 deletion status on the effect of nutlin-3 [95, 96]. The HMCLs 
that were used for those published in vitro studies also were not of p53 WT/- 
genotype [95, 96]. Therefore, our current findings unveiled the unknown efficacy 
of nutlin-3 on the p53 WT/- cases, as well as the condition under which the drug 
would be effective.  
 
5.4 PRIMA-1 and its p53-independent mechanism 
 PRIMA-1 is a first-in-class drug that was identified to specifically 
reactivate mutant p53 [98, 109]. Interestingly, the evidence from our current study 
strongly point towards a p53-independent mechanism of PRIMA-1 in MM. This 
notion was established based on the evidences showing an absence of p53-
pathway reactivation in the p53 mutant cells (RPMI-8226, U266 and KMS28BM), 
alongside a reduction of cell viability of all the HMCLs tested, be it in the 
WT/WT, Mut, WT/- or -/-, with a significantly more potent survival inhibition in 
the non-p53expressing cells (JJN3 and KMS11). These observations are in total 
agreement with a recent report by Saha et al. that have also shown that HMCLs, 
irrespective of their p53 status, were all responsive to PRIMA-1 treatment, with 
varying degree of IC50 [111]. However, they did not find significant difference in 
terms of the drug sensitivity between the p53 WT, mutant and null cell lines. This 
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discrepancy may very well be attributed to technical and experimental 
variabilities such as the usage of different cell lines to represent different p53 
status, cell seeding density prior to drug treatment and usage of different stocks 
and batches of HMCLs. Furthermore, PRIMA-1Met was used in their course of 
analysis whereas this project utilizes PRIMA-1. The more potent derivative of the 
drug with the presence of a methyl group may account for the higher sensitivity 
observed in their cells [111]. Nevertheless, these findings are consistent in 
suggesting that PRIMA-1 can kill HMCLs, regardless of their p53 abnormalities.  
It is also noteworthy that Saha et al. did not conduct analysis on the 
critical p53 WT/- MM cells [111]. We observed that the p53 WT/- HMCL (JJN3) 
that was endogenously lacking p53 mRNA and protein expression displayed 
significantly higher sensitivity to PRIMA-1 as compared to the WT/- cells that 
expresses at least some degree of mRNA and protein. This observation resembled 
the response seen in the p53-null cells (KMS11), indicating the dispensable role 
of p53 in PRIMA-1 activity. Essentially, this phenomenon was further validated 
when the downregulation of p53 protein to only 10% expression of its isogenic 
control counterpart in NCI-H929 render the cells more sensitive towards the drug. 
Paradoxically, the p53 mutant cells actually displayed higher IC50 than either the 
p53 deficient or wild type HMCLs. This intriguing finding is also in agreement 
with another unpublished data that demonstrated higher LD50 of TP53mut 
HMCLs than those with TP53del and TP53WT [173]. The fact that PRIMA-1 was 
found to be more efficacious in zero p53 background implicates the prominence 
of p53-independent mechanism behind PRIMA-1 cytotoxicity in MM.  
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However, it is also important to note that the ability of PRIMA-1 to kill 
p53 WT and mutant HMCLs albeit at higher concentrations suggests that p53 
dependent mechanism cannot be entirely ruled out. Even though transcriptional 
reactivation of mutant p53 was not observed, as shown by the absence of 
expression of the classical p53 targets (p21, MDM2 and PUMA) in our p53 
mutant HMCLs, it has been reported that PRIMA-1 could actually restore the 
transcription of one target but not the other, depending on tumor types [106]. The 
reason PRIMA-1 could also kill tumors with WT p53 has been proposed to be due 
to the possible misfolding of this protein, rendering it to be dysfunctional [98, 
174]. Therefore, the efficacy of PRIMA-1 observed in HMCLs with WT p53 at a 
higher concentration also indicates that the likely involvement of p53-dependent 
mechanism should not be exclusively omitted, though the current perspective now 
is that this mechanism may be of low significance. 
Validating our results, the killing power of PRIMA-1 in cancer cells 
deficient of p53 has also been essentially observed previously in some p53-/- solid 
tumors, such as osteosarcoma (Saos-2) [106], prostate cancer (PC3) [103] and 
hepatocellular carcinoma (Hep3B) [105]. In support of this notion, knocking 
down the mutant p53ser249, which often confer poor prognosis in HCC patients, 
in PLC/PRF/5 cell line further sensitized the cells to the cytotoxic effects of 
PRIMA-1. Even though PRIMA-1 treatment could also trigger an inhibition on 
the HCC cell survival in the presence of the mutant protein, this group of 
researchers hypothesized that the gain-of-function of this mutant protein may 
actually be masking the full potential and effects of mutant p53-independent 
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actions. Hence, eliminating this GOF protein would then promote increased 
sensitivity of the cells to the drug.  In support of this GOF conjecture, PRIMA-1 
treatment in a set of small cell lung carcinoma cell lines with low or undetectable 
level of mutant p53 caused a significant increase in the sub-G1 population [100]. 
In fact, these cell lines were found to be responsive to a lower dosage of PRIMA-
1, in which 50uM of treatment was already sufficient to cause up to 50% of cell 
death whereas, 100uM was required to bring about the same amount of apoptosis 
in the cell lines with high basal expression of its mutant p53. In addition, the 
dispensable role of mutant p53 in mediating PRIMA-1 toxicity was again 
highlighted when the prostate cancer cell lines, PC3 (p53-/-) and 22RV1 (p53WT) 
were also found to be significantly more sensitive towards PRIMA-1 than the 
mutant cell line tested (DU145), thus lending more support to the critical function 
of the mutant p53-independent mechanisms in mediating the drug toxicity [103].  
The potential evidence of PRIMA-1 acting in a mutant p53-independent 
manner in hematologic malignancy emerged when patient samples from AML 
and CLL the tumors of which predominantly contain wild type p53, were found to 
be responsive towards the drug, with a higher toxicity observed in the 17p(del) 
patients [108, 110]. Furthermore, evaluation of the PRIMA-1 sensitivity on mouse 
leukemia cells with no expression of p53 mRNA and protein also showed potent 
induction of apoptosis [174]. These published findings, together with our data, 
strengthened the importance of p53-independent-mechanism in mediating 
PRIMA-1 cytotoxicity, indicating the possible application of the drug not only in 
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MM cells with mutant p53 (albeit requiring higher dosage), but also in tumors 
with no p53 expression and in those with wild type p53. 
  
5.5 Molecular mechanism of PRIMA-1 in HMCLs 
One critical question is why do the HMCLs containing mutant p53 tested 
did not show a restoration of wild type p53 functions. As previously reported, a 
dissection into the biochemical and molecular effects of PRIMA-1 revealed that 
this drug acts through its active compound that binds to and forms adduct with the 
thiol groups on mutant p53, thus, modifying and restoring its wild type protein 
conformation and functions [98]. There is still no conclusion as to which Cys 
residues in the p53 core domain that could be modified by MQ or other PRIMA-1 
decomposition products. However, it has been postulated that Cys182, Cys229, 
Cys242 and Cys277 which are exposed on the surface of the core are more prone 
targets for modification [98]. Therefore, this means that the existing structural 
configuration of a particular mutant p53 can influence the level of exposure for 
the Cys residues, hence determining the extent of interaction with MQ, ultimately 
affecting responsiveness of the cells to the drug. In view of this, it is plausible that 
the mutant p53 proteins in the HMCLs used in this study, namely RPMI-8226 
(E285K), U266 (A161T) and KMS28BM (G105R), could have their mutant 
proteins being folded in a way that do not or only minimally allow the exposure 
of Cys residues, thus forbidding their interaction with MQ, altogether prohibiting 
the restoration of wild type transcriptional activity. Of course, this notion cannot 
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be confirmed until it is proven through imaging analyses using nuclear magnetic 
resonance and/or X-ray crystallography.  
Secondly, some previous studies have actually highlighted the possible 
role of mutant gain-of-function effects of mutated p53 in conferring resistance 
towards the drug. This mechanism was described by the increased sensitivity of 
HCC and breast cancer cells towards PRIMA-1 treatment after silencing the 
mutant p53 expression [105, 175].  In view of this, we hypothesize that this could 
also be the case for our mutant p53 in which this gain-of-function factor may be 
preventing the full effects of PRIMA-1, rendering the requirement for higher 
concentration to effectively kill the cells. Furthermore, mutant p53 has been 
shown to be subjected to mass ubiquitination and subsequently be degraded in the 
nucleolus after interacting with MQ [175], a finding that reflects the need to 
remove the gain-of-function effects to promote a conducive environment for cell 
death. Therefore, based on this, it is only relevant to assume that this mechanism 
is possibly already obliterated in our p53 mutant HMCLs as no obvious change of 
the p53 expression was observed after the drug treatment. This would probably 
cause the cells to retain the GOF effects and ultimately confer a greater resistance 
towards the drug as compared to the p53 WT and -deficient HMCLs. 
Cell death triggered by PRIMA-1 has been previously proven to be 
caspase-dependent [98, 111, 175]. In MM, when HMCLs were incubated with 
PRIMA-1 in the presence of pan-caspase inhibitor, Z-VAD-FMK, cell death was 
significantly rescued, emphasizing the need for executioner caspases, such as 
caspase-3 to induce apoptosis [111]. Recapitulating this observation, our Western 
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blot analysis also detected an obvious increase in the cleaved derivative of 
caspase-3 in both JJN3 and KMS11, as well as in NCI-H929-shp53.  
The intrinsic apoptosis pathway has already been described as an 
important death route for the PRIMA-1-treated cells. In response to the drug 
exposure, cancer cells displayed an activation of mitochondrial apoptosis 
mechanism with the upregulation of the pro-apoptotic BH3-only proteins, such as 
BAX and NOXA together with the simultaneous downregulation of the pro-
survival BCL-2 protein and a subsequent increase in the mitochondrial membrane 
permeability and the release of cytochrome C [99, 100, 112].  Consistent with this 
information from the literature, the involvement of mitochondria in executing 
PRIMA-1-induced apoptosis was also observed in our study models. We found a 
significant increase of NOXA expression with a concurrent downregulation of 
BCL-2, indicating that the intrinsic mitochondrial apoptotic response was taking 
place. In addition, cleaved caspase-9, the initiator caspase responsible for the 
mitochondrial apoptosis network, was clearly expressed.  
Having established this, the participation of extrinsic apoptosis pathway in 
accomplishing PRIMA-1 toxicity is nevertheless, still not well studied. In this 
regard, we also found an increase in the caspase-8 (initiator of extrinsic response) 
activity upon PRIMA-1 treatment, suggesting the activation of the extrinsic 
apoptotic pathway. This is a salient finding because the existing data on both solid 
tumors and MM have yet to establish the importance of this pathway. Importantly, 
the fact that both the mechanisms were found to be involved in our study model 
suggests that double apoptosis pathway activation may result in the amplification 
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of the effects conferred from the stimulation of only single pathway, thereby 
leading to a heightened apoptosis reaction.   
 
5.6 Activation of ER stress pathway in response to PRIMA-1 treatment 
Since the results thus far indicate that PRIMA-1 was killing MM cells in a 
p53 independent manner and that p53 dependent mechanism may be of less 
significance in our case, it is vital that the targeting pathway of the drug be 
identified so that a more thorough understanding of this compound can be 
achieved. GEP analysis and the evaluation of the gene ontology unveiled 
significant enrichment of ER stress-related genes upon PRIMA-1 treatment.  
HSP70, which is a chaperone molecule involved in protein folding in the 
endoplasmic reticulum [112, 125], displayed a significant increase in its 
expression level after the drug treatment in both the JJN3 and KMS11, suggesting 
increased unfolded proteins accumulation in the PRIMA-1 treated fractions. 
Importantly, this finding was consistent with the one reported by Saha et al. 
whereby HSP70 was also found to be increased in their panel of HMCLs upon 
PRIMA-1 treatment [111].  In parallel, the enhancement of the HSP70 protein 
expression has also been described in the lung adenocarcinoma cell line, including 
the p53-null-H1299 and its His175 mutant derivative [176]. In addition, our 
results also showed the induction of two other ER stress related genes, namely 
GADD34 and NOXA, further supporting the involvement of ER stress responses.  
Corroborating our GEP results, Western blot analysis also showed a robust 
activation of the ER stress pathway, with a marked upregulation of a series of 
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bona fide ER stress markers such as GRP78, CHOP and GADD34. NOXA, which 
has been reported to be involved in ER stress-mediated cell death [130, 131, 177], 
was also found to be potently elevated. Further validating ER-stress-driven-
cytotoxicity, knockdown of CHOP, a protein specifically regulating the ER stress-
induced apoptosis significantly reduced cell sensitivity to PRIMA-1. These 
findings provide strong evidence that ER stress is involved in PRIMA-1 toxicity.  
Further supporting our current data, the association of ER stress with 
PRIMA-1  has been reported by Lambert et al., in which the PRIMA-1 treatment 
in an osteosarcoma cell line also induced several genes associated with ER stress 
such as XBP1, NOXA and DNAJB2 [112]. In fact, this is the first and only other 
paper associating PRIMA-1 toxicity with ER stress. Even though their finding 
was observed in the p53 mutant cells, the fact that ER stress was shown to be 
engaged in the PRIMA-1 treatment response, in both their study model and ours, 
suggest a novel mechanism by which the drug can target and kill cancer cells. 
According to the earlier mentioned group, as p53 has been linked to the ER stress 
response by mediating the transcription of the ER stress-related downstream 
genes, such as XBP1 and NOXA [177, 178], it is possible that the restoration of 
wild type conformation of p53 in the His-273-Saos-2 cells was contributing to the 
ER stress pathway activation. This explanation is tentatively applicable for our 
HMCLs with mutant p53 and to some extend WT p53 but definitely not for the 
p53-deficient ones. In the p53 deficient cases, the generation of ER stress must be 
through a p53-independent route, indicating that PRIMA-1 potentially also targets 
proteins other than mutant p53 to induce UPR.  
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As described earlier, MQ is the final component of PRIMA-1 that binds to 
and alter Cys residues on the DNA- binding domain of mutant p53 [98]. Due to 
the fact that other intracellular proteins also contain Cys, it is plausible that 
PRIMA-1 or MQ binds to other cellular proteins and alters their endogenous 
activities, potentially interrupting with the protein homeostasis, and eventually 
activating the UPR. As PRIMA-1 was developed to specifically target the mutant 
p53, binding of MQ to proteins other than p53 may have different effects that 
have yet to be discovered. On this basis, we suggest that instead of promoting 
proper folding, PRIMA-1 could be causing a disorderly and unintended folding of 
proteins other than its specific target mutant p53. Mass accumulation of such 
misfolded proteins would then further enhance cellular duress. Moreover, besides 
MQ, there were actually two more breakdown products of PRIMA-1, which has 
not been characterized before [98], therefore it is unknown if they could at all 
contribute to the mechanism underlying the activation of intracellular ER stress 
response. For now, the relevant thought here is that extensive modification of 
thiols on other proteins by PRIMA-1 conversion products might induce changes 
in the cellular milieu that then disrupts protein homeostasis, resulting in p53 
independent cell death. Alternatively, we also postulate that MQ could possibly 
bind to ER stress-related proteins, altering their structure through adduct 
formations, decreasing their activation threshold and in turn sparking off ER 
stress-response activities more easily.  
In fact, the possible interaction of PRIMA-1 with proteins other than p53 
has been highlighted when it was found to restore the wild type activities of 
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mutant p63 and p73, homologues of p53 [179]. Another such evidence emerged 
when MQ was shown to be able to interact with another protein, selenoprotein 
thioredoxin reductase 1 (TrxR1) to inhibit its enzymatic activity [180]. This 
enzyme contains selenocystein (Sec) residues, which are more reactive than Cys 
due to its higher nucleophilicity and lower pKa, therefore, giving rise to the 
increased binding affinity of MQ to Sec. In this report, it was demonstrated that 
the mutagenesis of Sec render the inability of PRIMA-1 to inhibit its enzymatic 
function, thus indicating the importance of Sec residues for the MQ binding [180].  
As ER stress pathway is made up of three overlapping networks, it would 
then be important to identify the specific network that PRIMA-1 activates. As 
mentioned in the introduction, the IRE1/XBP1 pathway is critical for plasma cell 
differentiation, indicating the need for this pathway to sustain myeloma cells 
development and maturation. Emphasizing the need of IRE1 in MM cell survival, 
treatment of HMCLs with a specific small molecule inhibitor, STF-083010, which 
blocks the endonuclease activity of IRE1, saw a potent induction of apoptosis 
[156, 181]. With reference to this finding, PRIMA-1 could also possibly suppress 
the pro-survival effects of the IRE1/XBP1 pathway to favour apoptosis. Indeed, 
we did not observe any XBP1 cleavage upon PRIMA-1 exposure. Essentially, we 
found that PRIMA-1 could significantly rescue tunicamycin-induced XBP1 
cleavage. Thus, these data strongly supports the notion that PRIMA-1 was 
inhibiting the pro-survival IRE1/XBP1 activity to stabilize the pro-apoptotic 
platform in the cells. 
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In addition, ATF6 constituting the other arm of ER stress response, has 
been linked to both the pro-survival and pro-apoptotic mechanism in the UPR, 
depending on the level of stress imposed unto the cells [125]. In stressful 
condition, ATF6 works in partnership with ATF4 to transcribe the pro-apoptotic 
protein CHOP. Therefore, to determine if the surge of CHOP protein and mRNA 
was in any way due to ATF6 activation, and to concurrently elucidate if PRIMA-1 
activates the pro-survival or pro-apoptotic function of ATF6 pathway, the activity 
of ATF6 was investigated. Essentially, the protein expression of ATF6 displayed 
a gradual diminishment in a time dependent manner in JJN3, indicating a down-
regulation of its activity when the cells were subjected to the drug treatment. 
When the direct effects of PRIMA-1 on ATF6 were interrogated at the molecular 
level by performing ERSE reporter assay, a non-significant increase of its activity 
was observed. It also did not significantly enhance the high luciferase activity 
stimulated by tunicamycin. These observations collectively indicate that PRIMA-
1-induced-ER stress response was not associated with ATF6 activity. This also 
means that the upregulation of CHOP was not being transcribed by ATF6 but by 
ATF4. In line with this observation, the importance of ATF6 suppression in 
driving apoptosis in MM was highlighted when silencing of ATF6 has been 
shown to induce significant myeloma cell death [136]. Therefore, it is relevant 
and likely that PRIMA-1 acts to inhibit the adaptive and pro-survival responses of 
both IRE1/XBP1 and ATF6 pathways to spur and facilitate the PERK/CHOP 
functions in inducing apoptosis.  
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A previous study which performed individual knockdown of the three 
UPR sensors, IRE1, ATF6 and PERK, showed that the loss of any one sensor 
tended to elevate the activity of the remaining sensors, thus confirming the cross 
talk between these dynamic systems. Therefore, since both IRE1/XBP1 and the 
ATF6 pathway were tentatively suppressed in response to PRIMA-1 treatment, 
perturbation to the ER homeostasis automatically activates the remaining sensor, 
PERK, and subsequently induce the actions of its downstream components in 
mediating cellular toxicity.   
Consistent with this hypothesis, we found a robust activation of the PERK 
pathway as indicated in the Western blot and qPCR analysis. All the main 
components of PERK pathway, namely the p-PERK, p-eIF2a, ATF4, GADD34 
and CHOP showed increased expression with the exposure to PRIMA-1. 
Depletion of CHOP, the main apoptosis modulator in the ER stress pathway 
caused a significant rescue of PRIMA-1-induced apoptosis. This data strongly 
suggests that PRIMA-1 induce apoptosis in MM cells via PERK culminating in 
the actions of CHOP in executing the apoptosis response. The importance of 
PERK in establishing an ER stress-mediated apoptosis was indicated by a 
previous report demonstrating an impairment of mitochondrial apoptogenic 
potential in MM cells upon PERK suppression [136]. In fact, the attenuation of 
this arm of the ER stress network has also been shown to ameliorate 
chemotherapy-induced death in many other types of human tumors [125]. 
Therefore, this implicates that PERK/CHOP arm, but not the IRE1/XBP1 and 
ATF6 arms, is the important ER stress pathway mediating PRIMA-1 cytotoxicity.  
!140!
!
5.7 ROS generation is associated with activation of ER stress pathway 
 To probe deeper into the mechanism of ER stress, the role of ROS was 
taken into consideration. This is relevant given that ROS has been consistently 
linked to the ER stress induced apoptosis in cancers [157, 159, 160]. In line with 
this, we postulated that our HMCLs were dying in response to PRIMA-1 
treatment due to the detrimental effects exerted by ROS, resulting in the induction 
of ER stress signaling cascade. As opposed to our hypothesis, we found that ROS 
generation was actually a later event than UPR. Time point analysis revealed an 
increase DCFDA-positive cell population in PRIMA-1-treated JJN3 at later time 
points, i.e. starting from the16th hour, whereas ER stress markers were already 
elevated at the 6th hour. Furthermore, the exposure of PRIMA-1-treated cells to 
NAC, the specific ROS scavenger, attenuated the expression of late ER stress 
markers and significantly reversed the effects of PRIMA-1-induced cell death.  
Of relevance, the generation of ROS by PRIMA-1 has been previously 
described in some solid tumors, namely osteosarcoma, lung adenocarcinoma and 
breast cancer [98, 104, 180]. Investigation on osteosarcoma cells (Saos-2-His273) 
revealed a mutant p53-dependent increase of cellular redox imbalance with a 
subsequent generation of a more oxidized cellular condition [98]. Increased 
oxidation condition in the cells was also significantly observed at a later time 
point of 24 hours in Saos-2-His273. These investigators hypothesized that 
alkylation of thiols might regulate the activity of redox modulators of p53 [98]. 
The evidence on p53-independent induction of ROS by PRIMA-1 
surfaced when studies on lung adenocarcinoma and breast cancer cells also saw 
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an increase of ROS production irrespective of p53 status in the cells [104, 180].  
In order to explain this situation, Peng et al. demonstrated that PRIMA-1 could 
actually affect intracellular redox status by executing its thiol alkylation process 
on the selenocysteine residues of a thioredoxin enzyme, TrxR1 [180]. Inhibited 
TrxR1 reductase activity in turn causes it to act as a pro-oxidant NADPH oxidase 
that enables a subsequent generation of abundant free radicals and ROS. The 
pivotal role played by ROS in mediating PRIMA-1 toxicity was again highlighted 
when a synergistic effect was displayed between PRIMA-1 with hypoxia in 
cancer cells [104]. Since hypoxia is known to initiate a gradient of oxidative stress 
mediated by the presence of high H2O2, further enhancement of ROS content 
induced by PRIMA-1 in the cells incubated under a hypoxic condition 
automatically places the cells in a more oxidized milieu that is beyond their 
tolerance threshold. Therefore, these previous observations support the 
significance of ROS production in mediating the PRIMA-1-induced-toxicity. 
However, none of these reports relate the ROS induction with ER stress under 
PRIMA-1 influence. 
In view of this missing link, our data depicts a possible picture of PRIMA-
1 inducing ROS generation via ER stress responses. Furthermore, ROS 
production machinery lies in the mitochondria, and the fact that ER stress-induced 
apoptosis in our study models were shown to occur through the mitochondrial 
pathway, as evidenced by NOXA upregulation and BCL2 downregulation, we 
suggest that the increase in the MOMP upon PRIMA-1 treatment could cause the 
release of ROS that would create an acidic environment conducive for the 
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formation and accumulation of more unfolded proteins that already exists from 
PRIMA-1 treatment, thus supplementing the ER stress pathway activity in 
triggering massive apoptosis. Also, because we saw that the expression level of 
GADD34 and CHOP was most intense at 24 hours, it is possible that ROS 
generation starting at the 16th hour added more stress to ER, significantly 
supporting the persistent activation of the UPR, which is required to sustain the 
death inducing effects of PRIMA-1.  
 
5.8 Involvement of other possible pathways in mediating PRIMA-1 toxicity 
The current evidence from our work suggests the importance of 
PERK/CHOP in the ER stress network and ROS response as the underlying 
mechanisms mediating PRIMA-1 cytotoxicity.   However, like what have been 
mentioned in a previous paper [98], we also do not rule out other possible 
mechanisms playing a role in mediating PRIMA-1 induced cell death in MM. 
Indeed, our data hinted at the involvement of the p73 pathway in response to 
PRIMA-1 exposure. There was a significant increase of p73 expression at both 
the mRNA and protein level in the p53-deficient-JJN3 upon the drug treatment. 
This led us to hypothesize that in the absence of p53 in JJN3, p73’s role as a 
tumor suppressor was magnified in order to provide surrogate assistance to p53. It 
is pivotal to note that NOXA was also significantly elevated upon PRIMA-1 
treatment, and that it is also a direct target of p53, therefore, it is possible that p73 
was acting as a transcription factor in place for the absent p53, in driving the 
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transcription of NOXA, thus inducing a mitochondrial apoptotic response. 
However, this will have to be experimentally validated.  
The importance of p73 and NOXA in PRIMA-1 induced apoptosis was 
also made prominent by Saha et al. when silencing both genes in their study saw a 
substantial abrogation of apoptosis in the HMCLs tested [111].  Therefore, it is 
safe to say that p73 tumor suppressor pathway is also in part a critical apoptosis 
inducer in PRIMA-1-treated HMCLs. The potential direct or indirect effect of 
PRIMA-1 on the mechanism of p73 remains to be elucidated. 
On top of this, the involvement of other pathways has also been associated 
with the actions of the drug. For instance, a microarray analysis demonstrated that 
PRIMA-1Met has profound impact on global gene expression in a mutant p53-
dependent manner, whereby besides ER stress responsive genes, there was a 
marked change in expression of genes that are functionally related to cytoskeleton 
[112]. Essentially in MM, GEP analysis done in p53 wild type, mutant and null 
HMCLs has interestingly fished out some growth related genes, namely, c-Jun 
and EGR1 [111]. Functional in vitro studies in the same paper have also revealed 
a colony formation and cellular migration inhibition ability of PRIMA-1Met in 
both p53 WT (MM.1s) and mutant (RPMI-8226) HMCLs, indicating that genes 
associated with disease progression and metastasis could also be suppressed by 
the drug [111].  
These observations further emphasize the fact that PRIMA-1 is a cytotoxic 
agent that potentially targets multiple pathways. If this is really the case, it can 
help to rescue resistance of cancer cells, including MM, towards conventional 
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chemotherapy by attacking alternative pathways, should one pathway be defective 
or shut down due to various reasons.  
 
5.9 Clinical application of PRIMA-1 as a novel therapeutics for MM 
 MM cells produce an excessive amount of immunoglobulins, thereby 
resulting in an abnormally high basal ER stress level in the malignant plasma cells 
compared to normal plasma cells. Further perturbation to the protein homeostasis 
in these cells can then easily cause toxicity by switching the pro-survival mode in 
the cells to pro-apoptotic. Therefore, this dynamic and interesting property of 
myeloma can be exploited therapeutically considering that these traits render the 
cells to be more sensitive to ER stress-inducing compounds.  
Since we have shown strong association of PRIMA-1 with ER stress 
activation, we suggest that this drug possesses clinical translational value. The 
ability of this drug in targeting the Achilles heel of MM cells by compelling them 
to switch from their adaptive reactions to pro-apoptotic responses in the ER stress 
pathway serves as a strong indication that PRIMA-1 would be an attractive anti-
myeloma agent. Furthermore, this compound was cytotoxic to all the HMCLs 
tested, suggesting that PRIMA-1 is a versatile drug and that its usage could be 
extended for treatment of tumors of broader spectrum. Supporting the significance 
of our in vitro findings, PRIMA-1Met demonstrated similar efficacy in vivo by 
retarding the MM tumor growth harbouring mutant p53 in mice xenograft [111]. 
One important highlight from our PRIMA-1 study is that cells without p53 
expression were found to be significantly more sensitive to the drug. Since we 
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have earlier found that p53 monoallelic deletion cases may have different 
functionality of its p53 signalling, PRIMA-1 apparently represents an attractive 
and ideal therapeutic option for the WT/- cases without p53 expression. 
 Drug combination constitutes the main treatment protocol in the clinic; 
therefore, it is vital and reasonable to demonstrate the effects of PRIMA-1 in the 
presence of other standard treatment compounds. In this instance, the promising 
drug in MM, bortezomib was analyzed. To justify the selection of this compound 
as a combination partner with PRIMA-1 for this study, it has been widely 
associated with ER stress pathway activation [137, 182] and myeloma cells with 
high immunoglobulin production (high basal ER stress) has been shown to be 
more sensitive to bortezomib [132, 161]. Thus, we figured that PRIMA-1 could 
serve to increase the already high basal ER stress level in the cells, thereby, 
actively inducing the UPR to induce cell death.  
Indeed, this hypothesis was supported by the finding that JJN3 showed 
significantly decreased cell viability when exposed to combination of PRIMA-1 
and bortezomib as compared to treatment with either of the single agent, 
demonstrating an additive or synergistic effect at different concentrations. Of 
significance, PRIMA-1 was also able to partially rescue bortezomib resistance in 
the bortezomib-resistant HMCL, RPMI-8226-P100V, indicating its clinical 
potential in rescuing patients from bortezomib resistance.  
In support for PRIMA-1 to be incorporated into the standard treatment 
regime in the myeloma clinic, positive outcome from combination treatment of 
PRIMA-1 with other standard cytotoxic drugs has also been reported. In MM, 
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PRIMA-1 displayed great synergism with both dexamethosone and doxorubicin 
in vitro [111]. Apparently, the increased efficacy of these combinations in killing 
MM cells was also seen in vivo whereby there was a more rapid tumor regression 
in mice treated with combined agents as compared to the single agent and DMSO- 
treated counterparts [111]. Of relevance, two primary MM samples with 
hemizygous p53 deletions (high-risk group patients) displayed at least an additive 
cytotoxic effect in response to combination of PRIMA-1Met and dexamethasone, 
indicating that this drug poses great clinical relevance for this high-risk group of 
patients [111]. In fact, similar scenario has been reported in another blood cancer, 
AML, whereby PRIMA-1 displayed higher cytotoxicity to AML cells with p53 
hemizygous deletion, further reflecting the suitability of PRIMA-1 for treating 
patients suffering from this notorious genetic abnormality [108].  
Besides MM, the potent synergistic effects of PRIMA-1 with conventional 
therapeutic agents has also been demonstrated in other hematological 
malignancies, namely in AML (with danuorubicin) and in B-CLL (with 
fludarabine) [110], as well as in solid tumor. PRIMA-1 and cisplatin showed 
enhanced tumor suppressive ability in H1299-His175 cells, in both in vitro and in 
vivo settings [107].  
Further leveraging the clinical relevance of this compound, besides the 
conventional mitochondrial apoptotic response, we also found that PRIMA-1 
could cause a robust induction of the extrinsic apoptosis pathway. This 
observation is important because previous studies have documented a caspase-
dependent-apoptosis response in both solid tumors [98, 100] as well as in MM 
!147!
!
[111], nevertheless, involvement of both intrinsic and extrinsic pathway has never 
been reported. This is an additional bonus for the drug because should one of the 
apoptotic pathway has been shut down or have gone defective for some reasons, 
there would still be an alternative apoptosis route that can be undertaken by the 
cells. This ideal phenomenon would at least help to alleviate one of the factors 
contributing to conventional chemotherapeutic drug resistance. 
It is also noteworthy that the entire course of this project utilizes PRIMA-1 
concentration at the range of 10uM up to 100uM. Despite its relatively high 
concentrations required for optimum cytotoxic response in MM cells (IC50 of at 
least ~20uM), the concentration range of PRIMA-1 as well as its more potent 
derivative PRIMA-1Met was similarly needed to induce apoptosis in other tumor 
cell types [100, 103, 106, 107, 110, 112]. Moreover, toxicity studies in mice 
demonstrated that administration of high doses (up to 100mg/kg) of the drug into 
the xenograft system (including the MM models) did not yield any significant 
toxic effects, supporting its tolerability in an in vivo background [99, 100, 102, 
111]. What is worthy of mention is that the drug at such concentrations and doses, 
did not impose any significant toxicity to bone marrow microenvironment and 
hematopoietic progenitor cells, as opposed to the standard DNA damaging anti-
cancer agents [109, 111]. Of importance, the first-in-human study with PRIMA-
1Met has reported 60mg/kg as the maximum tolerated dose, which correlates to a 
maximum plasma concentration of about 300uM [109]. In this current project, we 
already saw a complete eradication of the MM cells at 100uM in all the HMCLs 
tested. This simply means that efficient killing of MM cells can already be 
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achieved at a dosage that is substantially lower than the reported maximum 
tolerated dose. Toxicity monitoring in human subjects showed that the drug is 
generally well tolerated, with only minor and reversible adverse effects reported 
such as fatigue, dizziness, headache and confusion [109].  Therefore, considering 
this safety profile of the compound, it would be feasible to utilize PRIMA-1 to 
taper the doses of the conventional chemotherapeutic drugs in an effort to 



















CHAPTER 6: CONCLUSIONS 
 
6.1 Concluding remarks 
17p13 deletion has been established as an important prognostic factor in 
MM [67, 78]. The current clinical scenario reflects an inadequacy of treatment 
options for this high risk patients presenting with hemizygous 17p13 deletion. In 
pursuit of exploring means to improve the treatment outcome in this patient group, 
a more specific biomarker is urgently needed so that the patients can be diagnosed 
into more accurate prognostic groups and then be specifically treated in a targeted 
manner. Therefore, this project aims to establish important biomarkers that can 
identify the molecular abnormalities of p53 in relation to their 17p13(del) status 
besides exploring some potential novel therapeutics for the prognostic 
improvement in these high-risk patients.   
In this study, we have provided compelling evidence that TP53 is the 
critical gene within the 17p13 minimally deleted region and is a haploinsufficient 
tumor suppressor in myeloma. One copy loss of the gene was already enough to 
diminish its endogenous dosage and abolish functionality. The main highlight of 
our finding is that not all cases of 17p13 deletion are similar and that the p53 
baseline protein expression level is critical in ascertaining the tumor suppressor 
activity of the remaining TP53 allele. We found that its endogenous dosage is a 
more critical determinant than its copy number status. This clinically important 
finding provides a platform for a more precise stratification of the 17p13(del) 
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patients and a more accurate determination of their response rate towards p53-
reactivating drugs.  
In relation to p53 endogenous level, we have importantly demonstrated 
that besides genetic deletion and mutations, various alternative mechanisms can 
also affect the p53 expression and its functional signaling in myeloma. We found 
that MDM2 over-expression and epigenetic regulation, such as aberrant p53 
promoter methylation and miRNA deregulation were important negative 
regulating factors of the intact TP53 allele in the WT/- cases. In these cases, we 
found that the effects of MDM2 over-expression can be reversed by the specific 
MDM2 inhibitors, nutlin-3 whereas p53 gene expression silenced in the promoter 
hypermethylation cases can be restored by using DNA methyltransferase inhibitor, 
5-Aza. These findings suggests that a proper understanding of mechanisms 
leading to the abnormal p53 pathways may informed on the most appropriate 
treatment approach to reverse p53 abnormalities. 
In view of this, we developed a powerful prognostic model, i.e. the MM-
p53-target-gene-signature (comprising of THBS1, GADD45 and PUMA) that we 
think can effectively describe p53 pathway deficiencies. This was established 
based on our discovery that defective p53 functions (at the gene or the protein 
level) ultimately manifests as an abolishment of p53’s transcriptional activities. 
Since this signature can potentially represent all the mechanisms leading to p53 
functional abrogation, we proposed that it would be a better prognostic marker for 
MM than the conventional detection of 17p13 deletion by FISH and p53 mutation 
by standard direct sequencing method. With this signature in place, the most 
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appropriate therapeutic approach can be tailored according the p53 pathway 
functional status in MM patients.  
Indeed, the application of this signature was proven feasible when we 
found that besides genetic status and copy number of TP53, the efficacy of nutlin-
3 in MM was closely associated with the induction of p53 downstream targets. In 
turn, the functionality of p53 downstream signaling totally depended on its basal 
expression level. Therefore, we propose for basal p53 protein expression to be 
used as a first line selection marker for nutlin-3 treatment. In case this information 
is not available, the useful MM-p53-target-gene signature can then function as the 
alternative predictive marker in place of the basal p53 expression level.   
Further supporting the practicality of the above biomarkers, the defective-
mutant-p53 cells and WT/- cells that did not possess funtional basal p53 
endogenously indeed demonstrated an absence of its downstream target gene 
expression, resulting in a complete resistance to both genotoxic (etoposide) and 
non-genotoxic (nutlin-3) stimulations. To address this resistance problem, we 
have then explored another p53-reactivating agent, PRIMA-1.  
Our data suggest that PRIMA-1 can be utilized as a versatile anti-
myeloma agent to target cases with or even without p53 abnormalities. 
Translational value of this compound was further amplified when we found that it 
can be an effective treatment option for WT/- cases with no p53 expression, as we 
observed a significantly higher efficacy against HMCLs that are p53-deficient. 
Essentially, interrogation of the molecular biology of PRIMA-1 has led us to a 
novel discovery of the involvement of ER stress responsive pathway in PRIMA-
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1-mediated-toxicity in the MM cells, whereby the PERK / CHOP route of the ER 
network constituted the main driver for apoptosis. 
Of importance, our results also showed potent therapeutic synergism 
between PRIMA-1 and bortezomib, thus providing a possible avenue to overcome 
therapeutic resistance to bortezomib. A recent study suggests that one of the 
important mechanisms determining sensitivity to bortezomib is elevated ER stress 
and UPR in the cells [132, 161] and that the cells with low levels of ER stress and 
UPR are more resistant to bortezomib [138]. Our results showing that PRIMA-1 
induced significant ER stress provide a clear mechanistic explanation underlying 
the synergistic effect between PRIMA-1 and bortezomib. PRIMA-1 is therefore 
worthy of further development as a therapeutic agent in MM. 
Summarizing our main findings, here we are proposing a possible 
treatment protocol that can be applied clinically for patients harbouring 







Figure 6.1. Our proposal on the potential treatment protocol for patients 
with differential p53 abnormalities. From conventional FISH and sequencing 
methods, TP53 genotype of MM cells are firstly determined. Then, this should be 
correlated with their basal expression level of p53 and its target gene signature. If 
the p53 expression and signature is positive, patients are to put under standard 
therapy with nutlin-3 treatment protocol. If there is an absence of basal p53 and 












6.2 General conclusion 
Overall, the current project provided new insights about p53 abnormalities 
in MM and how different p53 status can affect the integrity of its downstream 
functional pathway. The findings from this research carry multiple translational 
values, whereby spectrum of p53 dysfunction and p53 gene signature can be 
employed as both the predictive and prognostic biomarkers in pursuit for 
development of more effective and targeted therapies which are specific to 
different p53 genetic make-up. We have also shown the promises held by some of 
the p53-reactivating agents which we reckon can potentially change the current 
treatment scene for the 17p13(del) patients.  
 
6.3 Criticisms and future work  
While the results have helped established a novel and powerful prognostic 
models for the 17p13(del) patients and points to the several potential avenues by 
which these patients can be targeted, there are several points and future 
experiments that can be made to strengthen these conclusions. 
 
6.3.1 Haploinsufficiency of p53 in MM 
  From the data generated using HMCLs, we have convincingly shown 
haploinsufficient property of p53 in MM and their level of responsiveness to 
nutlin-3, nevertheless, it would be ideal to establish its clinical validity by 
conducting the similar experiments in primary patient samples. Taking into 
account the limited availability of these samples on top of their fastidious in vitro 
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culturing conditions, it is not possible to perform all of these functional 
experiments using patient samples especially for the extensive characterization 
and investigation that we have performed throughout. However, simple 
experiments such as detecting the basal p53 level and associating its expression 
level to their sensitivity towards nutlin-3 in the samples that have been identified 
as WT/- by FISH, may still be feasible. This way, we can directly extrapolate data 
from cell lines to patients, thus, providing a more accurate evidence for the 
potential clinical application of nutlin-3.  
 As basal p53 is an important determinant of the functional response of p53 
in the WT/- cases, it is still unknown about the prognostic implication in patients 
that have two intact alleles of TP53 but display low or zero expression at the 
mRNA level [143]. Therefore it is worthwhile to pursue similar experiments on a 
HMCL that has these characteristics in order to accentuate the relevance of nutlin-
3 application based on wild type p53 expression rather than copy number of its 
gene. This is also important to prove that not all WT/WT events has an intact p53 
pathway and that every step in customizing the treatment regime for these patients 
should be undertaken with the knowledge of whether basal p53 expression is 
present or not. 
 The fact that basal expression of p53 must be sufficient to confer a 
responsive downstream activity has led us to ponder exactly how much basal level 
of the mRNA and protein is necessary. In view of this, it would be crucial to 
delicately titrate the expression level of p53 in the functional studies. To achieve 
this objective, a tet-on-tet-off expression system whereby p53 expression can be 
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manipulated and altered by gradually increasing or decreasing the concentration 
of tetracycline or its derivative docycycline, can be useful.  
As mentioned in chapter 2, besides TP53, the minimally deleted region of 
17p13 comprise of a number of other important genes. We have identified 32 
genes in this location from our MMRC dataset analysis, and a brief literature 
search revealed two other potential tumor suppressor genes residing in this area, 
namely, KDM6B (histone demethylase) and PER1 (circadian gene). KDM6B has 
been found to be responsible for the activation of INK4A-ARF-induced 
senescence [183], wheareas the deregulation of PER1 has been  closely associated 
with various cancers [184, 185]. Given the anti-tumorigenesis properties of these 
genes, it is unknown if their concurrent deletion in 17p13 may cooperate with p53 
haploinsufficiency to drive myelomagenesis. In line with this hypothesis, in the 
future, it would be interesting to delineate the critical value of these important 
genes in 17p13. This hypothesis can be pursued by performing single knockdown 
and combinatorial knockdown of these genes with TP53. 
 
6.3.2 PRIMA-1 in myeloma 
 We have shown that on top of ER stress elements, p73 was also 
significantly upregulated in response to PRIMA-1 treatment. Even though p73 has 
actually been demonstrated as an important apoptosis inducer in PRIMA-1-treated 
myeloma cells [111], we do not know if it has any association with ER stress 
response activities. Furthermore, p53 was linked to ER stress as XBP1 was found 
to contain a putative p53 responsive element [112] but there is still no such 
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documentation for its homologue p73. Hence, it would be interesting to execute a 
study on the possibility of p73 being involved in the ER stress pathway. In 
addition, NOXA, which was upregulated upon PRIMA-1 treatment in the absence 
of p53, hints at possible transcriptional activation by p73. This possibility can be 
examined by performing chromatin immunoprecipitation to check for the binding 
of p73 to the p53-RE on NOXA promoter, and promoter reporter assay to 
examine its ability to drive the transcription of NOXA. This may provide the link 
between p73, ER-stress and NOXA.  
Furthermore, the IRE1 arm of the ER stress network can also steer 
towards the pro-apoptotic direction (instead of undergoing the pro-survival 
XBP1s way) mediated by the c-Jun N-terminal kinases (JNK) pathway. Also, the 
position of ROS in the whole network is still very vague. Therefore, the unknown 
role of these factors in PRIMA-1-induced-toxicity deserves further interrogation 
to connect the dots to better clarify the pro-apoptotic mechanisms of PRIMA-1 in 






Figure 6.2. The potential connection between p73-PERK-IRE1-Noxa upon 
PRIMA-1 induction in MM. Dotted arrows indicate possible links that have yet 
to be elucidated between the factors.  
 
 Another intriguing finding derived from this part of the project was the 
fact that abolition of p53 expression confers a significantly increased sensitivity in 
the HMCLs as compared to its parental cells containing wild type p53. The 
factors that influence the increased sensitivity of MM cells to PRIMA-1 in a p53-
deficient background should be sought. In this regard, global gene expression 
analysis comparing H929-shCtrl against H929-shp53 should be informative, after 
which relevant functional assays should then be conducted to investigate the top-
hit genes.  
 Again, the clinical validity of ER-stress induction by PRIMA-1 should 
also be established in the primary patient samples so that the clinical relevance of 
our in vitro data can be proven. It is also worth-noting that using PRIMA-1 
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instead of PRIMA-1Met in our experiments may be one of the setbacks in this 
project, therefore, exploring the efficacy of PRIMA-1Met and its potential ability 
to induce ER stress responses in MM would serve as one of the relevant future 
studies as the methylated derivative is the one that is currently being tested in 
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Table S1. List of antibodies used for Western blot analysis. 
Antibodies Company Dilution 
p53 (DO-1) Santa-Cruz 1:2000 
p-p53 (Ser-15) Cell Signalling 1:500 
p21 Cell Signalling 1:1000 
MDM2 Santa Cruz 1:2000 
PUMA Cell Signalling 1:1000 
Noxa CalBiochem 1:1000 
c-PARP Cell Signalling 1:2000 
Caspase-3 Cell Signalling 1:2000 
Caspase-8 Cell Signalling 1:2000 
Caspase-9 Cell Signalling 1:2000 
Gapdh Santa Cruz 1:5000 
CHOP Cell Signalling 1:1000 
eIF2a Cell Signalling 1:1000 
p-eIF2a Cell Signalling 1:500 
GRP78 Cell Signalling 1:1000 
p73 Abcam 1:1000 
Gadd34 Abcam 1:1000 
P-PERK Santa Cruz 1:500 
BCL-2 Santa Cruz 1:500 
MCL-1 Santa-Cruz 1:500 
Goat anti-mouse Santa Cruz 1:5000 
Goat anti-rabbit Santa Cruz 1:5000 








Table S2. List of primer sequences used for quantitative Real-time PCR. 
 































































Table S3. Methylated and unmethylated primer sequences for p53 methylation 
specific PCR. 
 



















Table S4. Summary of immunohistochemical double stains conditions. DAB, 
diaminobenzidine (brown stain); AP, alkaline phosphatase (red stain) 
 
 
Antibody Source Clone Dilution Retrieval Incubation Chromogen 
CD138/P53 
CD138: DAKO MI15 1:100 ER2-20' 15' DAB 
P53: DAKO DO-7 1:100 ER2-20' 15' AP 
CD138/MDM2 
CD138:DAKO MI15 1:100 ER2-20' 15' DAB 











Table S5. Genes located at the minimally deleted region of 17p13 in MMRC 
dataset. 
 
Chr Start End Strand Genome Gene_id Symbol 
17 7512445 7531642 - 36.3 7157 TP53 
17 7532520 7547544 + 36.3 55135 WRAP53 
17 7549245 7555418 + 36.3 1949 EFNB3 
17 7563764 7677783 + 36.3 146754 DNAH2 
17 7598363 7599019 + 36.3 118432 RPL29P2 
17 7683960 7698843 + 36.3 23135 KDM6B 
17 7699109 7700142 + 36.3 92162 TMEM88 
17 7700728 7701897 - 36.3 84316 LSMD1 
17 7702038 7706325 + 36.3 124637 CYB5D1 




17 7750166 7750303 + 36.3 677763 SCARNA21 
17 7757365 7760499 - 36.3 284023 LOC284023 
17 7766752 7773478 - 36.3 9196 KCNAB3 
17 7774392 7775988 - 36.3 58485 TRAPPC1 
17 7776198 7793621 + 36.3 116840 CNTROB 
17 7846713 7864382 + 36.3 3000 GUCY2D 
17 7883083 7893177 + 36.3 247 ALOX15B 
17 7916679 7931746 - 36.3 242 ALOX12B 
17 7939943 7962532 - 36.3 59344 ALOXE3 
17 7965024 7968127 - 36.3 84667 HES7 
17 7984515 7996427 - 36.3 5187 PER1 
17 8003189 8007017 - 36.3 6844 VAMP2 
17 8017021 8020439 - 36.3 84314 TMEM107 
17 8032376 8034115 - 36.3 54785 C17orf59 
17 8048774 8054608 - 36.3 9212 AURKB 
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17 8066482 8067138 - 36.3 284029 C17orf44 
17 8070918 8092138 - 36.3 80169 C17orf68 
17 8093362 8114528 + 36.3 5198 PFAS 
17 8131807 8138895 - 36.3 399512 SLC25A35 
17 8132714 8134130 + 36.3 29098 RANGRF 
17 8154315 8166554 + 36.3 22899 ARHGEF15 





































HMCLs were treated with increasing concentration of etoposide for 6 hours to 
induce genotoxic stress in the cells. Protein lysate were harvested from the treated 
cells and were analyzed for total p53, phospho p53 (ser15), MDM2, p21 and 
PUMA. Phospho p53 was tested to check for the presence of DNA damage upon 









   
 
MM.1s was transfected with a pool of p53 siRNAs (100nM) for 24 hours. Cells 











(A) Increasing concentration of 5-Aza treatment caused inhibition of cell survival 
in XG6. (B) p53 mRNA level increased upon 5-Aza treatment. (C) MSP analysis 








DMSO! 58Aza!2.5uM! 58Aza!5uM! 58Aza!7.5uM!
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